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University of Connecticut, 2015 
 
The central aim of the present research was to characterize aspects of the instigation and 
treatment of Parkinsonian resting tremor using a pharmacological rodent model, the tremulous 
jaw movement (TJM) model. These studies employed the TJM model to investigate the 
neurochemical and electrophysiological changes that are associated with tremorogenesis, and to 
test novel therapeutic agents for the treatment of resting tremor. Experiment 1 established a 
mouse model of Parkinsonian resting tremor using the anticholinesterase galantamine. In 
experiment 2, the novel antiparkinsonian agent safinamide attenuated TJMs induced by the 
anticholinesterase galantamine, the muscarinic agonist pilocarpine, and the dopamine D2 
antagonist pimozide. In experiment 3, the MAO-B inhibitor deprenyl attenuated TJMs induced 
by the VMAT-2 inhibitor tetrabenazine (TBZ). TBZ administration decreased extracellular DA 
levels in the ventrolateral striatum (VLS), and co-administration of deprenyl blunted this effect.  
The aim of experiment 4 was to characterize the effect of the SSRI fluoxetine (FLX) on the 
motor dysfunctions induced by TBZ and investigate the neural mechanisms involved. Co-
administration of FLX increased TBZ-induced TJMs and decreased locomotor activity compared 
to TBZ alone. Co-administration of the 5-HT2A/2C antagonist mianserin attenuated the increase in 
TJMs induced by co-administration of TBZ with FLX. Co-administration of TBZ and FLX 
decreased DA tissue levels in the rat VLS compared to TBZ alone, and co-administration of 
mianserin with TBZ and FLX attenuated this effect, increasing DA tissue levels compared to the 
TBZ/FLX condition. The fifth set of studies examined if tremor-related local field potential 
(LFP) activity could be recorded from motor cortex or subthalamic nucleus (STN) during TJMs 
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induced by the muscarinic agonist pilocarpine. Pilocarpine induced a robust TJM response that 
was marked by rhythmic electromyographic activity in the temporalis muscle. TJM epochs were 
characterized by increased LFP power in the tremor frequency range in both neocortex and STN. 
Tremor activity was not associated with increased power in the beta frequency band. These 
studies collectively extended and validated the TJM model, contributing to the ultimate goal of 
this line of research, which is to characterize the conditions associated with tremorogenesis in 
order to develop specifically-targeted therapeutic strategies. 
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Chapter 1: Parkinson’s Disease: Pathology, Symptoms, and Treatments  
Parkinson’s Disease and Parkinsonism  
 There are currently 1 to 2 million cases of Parkinson’s Disease (PD) in the United States 
and several million worldwide, making it the second most common neurodegenerative disorder 
(Nussbaum and Ellis, 2003; Ostrem and Galifianakis, 2010). Age is considered the strongest risk 
factor for PD, as it affects 1-2% of the population over the age of 65, and more than 3% of those 
over the age of 85. Given the current aging of the population, both the prevalence of PD and its 
national economic burden are expected to increase substantially as the population continues to 
age (Ostrem and Galifianakis, 2010; Shulman et al., 2011; Kowal et al., 2013). Conservative 
projections suggest that the number of individuals diagnosed with PD will likely double between 
2010 and 2040 (Kowal et al., 2013). PD is typically diagnosed between age 70 and 80 and 
progresses chronically and slowly until death, on average 15 years after initial diagnosis 
(Shulman et al., 2011). Upon postmortem examination of brains of PD patients, researchers have 
identified the presence of Lewy bodies and Lewy neurites (filamentous, α-synuclein-rich protein 
aggregates found in the cytoplasm and processes, respectively, of neurons; Nussbaum and Ellis, 
2003). However, the neuropathological hallmark of PD is the death of dopamine (DA) producing 
cell bodies in the substantia nigra pars compacta, which causes the degeneration of the 
nigrostriatal pathway and depletion of DA in striatal areas (Hornykiwicz, 1973). According to 
models of basal ganglia function, this degeneration of nigrostriatal neurons input leads to a net 
increase in inhibitory output from the globus pallidus interna (i.e., medial globus pallidus) and 
the substantia nigra pars reticulata, ultimately affecting the function of the motor cortex and 
brainstem motor areas (Hornykiwicz, 1973; Shulman et al., 2011).    
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Idiopathic PD is a member of a broader family of movement disorders known as 
Parkinsonism. While idiopathic PD is by far the most common form of Parkinsonism, drug 
administration is the second most common (Alvarez et al., 2007; Shulman et al., 2011). Drug-
induced Parkinsonism (DIP) can result from administration of pharmacological agents that 
interfere with DA transmission such as DA antagonists (e.g. haloperidol, pimozide) and DA 
depleting agents (e.g. reserpine, tetrabenazine) (Marsden et al., 1975; McEvoy, 1983; Arbaizar et 
al., 2008). Thus, DIP has been associated with the administration of a variety of typical and 
atypical antipsychotics, antiemetics, antihypertensives, gastrointestinal prokinetics, and 
antivertigo agents (Mena and de Yébenes, 2006; Alvarez et al., 2007; Shin and Chung, 2012).   
Additionally, cholinomimetic administration can induce or exacerbate Parkinsonian motor 
symptoms. Anticholinesterases are the primary treatment for Alzheimer’s disease, and several 
clinical studies indicate that patients have developed parkinsonian motor side effects (Iwasaki et 
al. 1988; Ott and Lannon, 1992; Kao et al., 1993; Keltner, 1994; Aarsland et al. 2003). 
 
Parkinsonian Resting Tremor and the Tremulous Jaw Movement Model  
Parkinsonism is characterized by several cardinal motor symptoms: resting tremor (3-7 
Hz), bradykinesia (slowed movement), akinesia (lack of initiation of spontaneous movement), 
and rigidity (increased muscular tone, passive resistance to movement) (Marsden et al., 1975; 
Findley, 1988; Bergman et al,. 2002, Ostrem and Galifianakis, 2010; Shulman et al., 2011) 
Parkinsonian resting tremor, defined as a “rhythmic, oscillatory, involuntary movement,” 
(Ostrem and Galifianakis, 2010) is the most common hyperkinetic movement associated with 
parkinsonism, and occurs in a frequency range of 3-7.5 Hz, which is distinct from dyskinesias (1-
2 Hz), essential tremor (8 Hz), and postural tremors (8-12 Hz) (Findley et al., 1981, Marsden, 
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1984; Deuschl et al., 1996, 2000). Parkinsonian resting tremor most frequently presents 
unilaterally in the distal upper extremities as a “pill rolling” movement, but typically spreads 
bilaterally, affecting the upper and lower limbs, facial muscles, and the jaw, a condition known 
as “rabbit syndrome” (Weiss et al. 1980; Salamone et al., 1998; Deuschl et al., 2000; Ostrem and 
Galifianakis, 2010).  
Rodent models have been essential to the scientific study of PD, and are frequently used 
to investigate both the underlying pathology and novel treatment strategies (Cenci et al., 2002; 
Betarbet et al., 2002). A number of rodent tests exist to assess the motor functions associated 
with akinesia and bradykinesia (e.g. catalepsy and locomotor activity assessment), yet resting 
tremor is the most common and easily recognizable symptom of PD and, thus, has been 
increasingly studied in recent years (Jankovic, 2008; Ostrem and Galifianakis, 2010). Currently, 
the tremulous jaw movement model is the most widely used rodent model for studying 
parkinsonian tremor. Tremulous jaw movements (TJMs) are defined as “vertical deflections of 
the lower jaw that resemble chewing but are not directed at any particular stimulus” (Salamone 
et al., 1998, 2005). In rats, the ventrolateral neostriatum (VLS), the striatal region responsible for 
orofacial movements and forepaw motor control, is the striatal region associated with the 
production TJMs (Salamone et al., 1990; Jicha and Salamone, 1991; Salamone et al., 1993). 
Local infusion of the neurotoxin 6-hydroxydopamine (6-OHDA) into the VLS has been shown to 
induce TJMs, while infusion into other striatal areas (e.g. anteroventromedial striatum, 
dorsolateral striatum, nucleus accumbens) does not (Finn et al., 1998; Jicha and Salamone, 
1991).  
TJMs in rats can also be induced by many of the same pharmacological agents that are 
responsible for DIP in humans. Interference with DA transmission, through the administration of 
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either DA antagonists (e.g. pimozide, haloperidol) or DA-depleting agents (e.g. reserpine, 
tetrabenazine), has been extensively shown to result in the production of TJMs in rats (Baskin 
and Salamone, 1993; Steinpreis et al., 1993; Salamone and Baskin, 1996; Salamone et al., 1998; 
Correa et al., 2004; Ishiwari et al., 2005; Salamone et al., 2008; Betz et al., 2009; Podurgiel et al., 
2013a). Tetrabenazine (TBZ) is a reversible inhibitor of vesicular monoamine transporter 2 
(VMAT-2) that is prescribed for treatment of chorea associated with Huntington’s disease (HD). 
VMAT-2 is present in the brain and is responsible for transporting catecholamines from the 
cytoplasm into synaptic vesicles. TBZ and has the highest binding density in DA-rich areas of 
the brain including the caudate, putamen, and nucleus accumbens (Pettibone, 1984a, 1984b; 
Thibaut, 1995) and thus inhibits the storage of DA, resulting in profound DA depletion. 
Accordingly, Parkinsonism is one of the most common adverse effects observed in HD patients 
taking TBZ for the treatment of chorea (Kenney et al., 2007; Frank, 2009). TBZ administration 
in rats has recently been established as a pharmacological model of Parkinsonism, as it induces 
TJMs and catalepsy and suppresses locomotor activity (Podurgiel et al., 2013a). Alterations in 
acetylcholine (ACh) transmission via administration of muscarinic agonists (e.g. pilocarpine) and 
anticholinesterases (e.g. tacrine, galantamine) have also been implicated in the production of 
TJMs (Salamone et al. 1986; Baskin et al., 1994; Mayorga et al., 1997; Salamone et al., 1998; 
Collins et al., 2010a; Collins et al., 2011). Studies employing freeze frame video analysis show 
the local frequency of TJMs is 3-7.5 Hz, which corresponds to the frequency range characteristic 
of Parkinsonian resting tremor (Salamone et al. 1996, 1998; Finn et al., 1997; Mayora et al., 
1997; Cousins et al., 1998; Ishiwari et al., 2005; Collins et al., 2011). Furthermore, 
electromyography (EMG) recordings from the lateral temporalis muscle (the jaw-closing muscle 
that has been implicated in TJM activity) in rats show consistent, rhythmic bursts of EMG 
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activity in the 4-5 Hz frequency range during burst TJMs, again consistent with the frequency 
range of Parkinsonian resting tremor (Cousins et al., 1998; Collins et al., 2011). TJMs in rats can 
be attenuated using antiparkinsonian agents including L-DOPA (Cousins and Salamone, 1996; 
Cousins et al. 1997) DA agonists (Baskin and Salamone, 1993; Cousins et al., 1997; Salamone et 
al., 2005) amantadine (Cousins et al., 1997), muscarinic antagonists (Steinpreis et al., 1993; 
Cousins et al., 1997; Mayorga et al., 1997; Betz et al., 2009), and adenosine A2A antagonists 
(Correa et al. 2004; Salamone et al., 2008; Betz et al., 2009; Collins et al., 2010a, 2011, 2012; 
Salamone et al., 2013; Santerre et al., 2012;  Podurgiel et al., 2013a). Furthermore, TJMs in rats 
can also be attenuated by deep brain stimulation of the subthalamic nucleus (STN) (Collins-
Praino et al., 2013).  
More recently, researchers have extended the TJM model to mice, thereby providing a 
platform for examining the effects of various genetic manipulations on parkinsonian tremor. Like 
rats, TJMs are induced in mice after administration of the DA-depleting agent tetrabenazine 
(Podurgiel et al., 2013), and the muscarinic agonist pilocarpine (Salamone et al., 2013); the 
adenosine A2A antagonist MSX-3 is capable of attenuating TBZ and pilocarpine-induced TJMs 
(Salamone et al., 2013; Podurgiel et al., 2013). Pilocarpine-induced TJMs in mice also occur 
primarily in bursts with a peak frequency of 3-7.5 Hz (Salamone et al., 2013). Furthermore, 
adenosine A2A receptor knockout (KO) mice show a reduction in TJMs after administration of 
TBZ (Podurgiel et al., 2013) or pilocarpine (Salamone et al., 2013) compared to wild type (wt) 
controls. Thus, extending the TJM model to mice has given researchers means to investigate a 
new dimension of Parkinsonism and tremorogenesis. 
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Pharmacological Treatment Regimens for the Motor Symptoms of PD 
 3,4-dihydroxy-L-phenylalanine (levodopa or L-DOPA) is a naturally occurring amino 
acid precursor to DA that was first given to PD patients in 1961 (Tolosa et al., 1998). After oral 
ingestion, L-DOPA is actively transported from the small intestine into systemic circulation, and 
once it crosses the blood brain barrier (BBB) it is rapidly converted to DA via the enzyme 
aromatic L-amino acid decarboxylase (AAAD) (LeWitt, 2008). In order to inhibit the conversion 
of L-DOPA to DA outside the central nervous system, L-DOPA is often coadministered with a 
peripherally acting AAAD inhibitor (either carbidopa or benserazide) (LeWitt, 2008). 
Coadministration of levodopa and an AAAD inhibitor remains the most effective medication 
available for the treatment of the motor symptoms of PD (Pedrosa and Timmermann, 2013). 
After oral ingestion, patients typically experience the therapeutic effect within 15 to 30 minutes 
marked by improvements in speech, dexterity, and gait (LeWitt, 2008). Patients in the early 
stages of PD experience consistent, sustained therapeutic responses to levodopa that lasts until 
the next dose (Ostrem and Galifianakis, 2010). However, within 5 years up to 50% of patients 
taking levodopa develop motor fluctuations (i.e., rapid fluctuations between the “on” state where 
patients show good response to the medicine, and the “off” state where they show little to no 
response to the medication) dyskinesias, or both (Nutt, 2001; Holloway et al., 2004; Stacy, 
2009).  
 DA agonists (e.g. pramipexole, ropinerole) have been used regularly to treat the motor 
symptoms of PD since the discovery of the benefits of bromocriptine in 1974 (Tolosa et al., 
1998).  DA agonists are often prescribed to patients in the early stages of PD as a monotherapy 
or in conjunction with levodopa (Pedrosa and Timmermann, 2013). When DA agonists are used 
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as an adjunctive therapy, PD patients experience a 20% to 40% reduction in off states, equal to 
an average of 2 hours per day (Bonuccelli, 2003).  
 Monoamine oxidase type B (MAO-B) is one of the key enzymes responsible for DA 
metabolism in the brain (Youdim and Bakhle, 2006). Deprenyl (Selegiline; ((R)-(-)-N-α-
Dimethyl-N-2-propynylbenzeneethanamine hydrochloride; ((R)-(-)-Deprenyl) is a potent, 
irreversible MAO-B selective inhibitor that been available for over 30 years for the treatment of 
motor symptoms in early and late stage PD (Schapira et al., 2011; Fabbrini et al., 2012). 
Deprenyl is well tolerated in PD patients, with side effects/adverse reactions (e.g. sleeplessness, 
nausea, vomiting, dizziness, dry mouth, orthostatic hypotension and dyskinesias) occurring in 2-
5% of patients, levels comparable to placebo (Riederer and Laux, 2011). When taken as a 
monotherapy in early PD, deprenyl delays the need for the introduction of L-DOPA (Fabbrini et 
al., 2012). As an adjunct treatment to L-DOPA, deprenyl prolongs the effectiveness of L-DOPA 
while reducing motor fluctuations (Riederer and Laux, 2011). Furthermore, deprenyl as an 
adjunct to L-DOPA enhances cognition, affect, and quality of life compared to L-DOPA or DA 
agonists alone (Krishna et al., 2014). Safinamide ((S)-(+)-2-[4-(3-fluorobenzyloxybenzylamino) 
pro-panamide]methanesulfonate (1:1 salt) is a potent, highly selective and reversible inhibitor of 
MAO-B that also reduces DA uptake, blocks voltage-dependent sodium channels, modulates N-
type calcium channels, and reduces glutamate release (Marzo et al. 2004; Fariello 2007; Onofrj 
et al. 2008; Schapira 2010; Stocchi 2012). By doing so, animal studies have revealed that 
safinamide exerts neuroprotectant, anticonvulsant, and antiparkinsonian properties (Salvati et al. 
1999; Fariello et al. 2000). Safinamide has an excellent therapeutic and safety margin and is 
currently in Phase III clinical trial development as an add-on therapy to levodopa or DA agonists 
for PD patients (Marzo et al. 2004; Onofrj et al. 2008; Schapira 2010; Stocchi 2012).  
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 Adenosine A2A receptors are densely concentrated in the striatum where they are 
colocalized with DA D2 receptors on enkephalin-positive medium spiny neurons (Ferre et al., 
1997, 2001). Research has shown that these receptors converge on the same cAMP-associated 
signal transduction mechanism and exert opposing effects (Ferre et al., 2008). DA D2 receptors 
are linked to the g-protein Gi and inhibit adenylate cyclase, while A2A receptors are linked to the 
g-proteins Gs/Golf and activate adenylate cyclase (Ferre et al., 1997; 2001, 2008; Iversen et al., 
2009). This interaction has led researchers to investigate the use of adenosine A2A antagonists as 
a non-dopaminergic treatment for the motor symptoms of PD. Studies in rodents have shown that 
A2A antagonists are capable of attenuating tremulous jaw movements induced by various DA-
depleting agents, DA antagonists, and cholinomimetics (Correa et al. 2004; Salamone et al., 
2008; Betz et al., 2009; Collins et al., 2010a, 2011, 2012; Salamone et al., 2013; Santerre et al., 
2012; Podurgiel et al., 2013a). Recently, istradefylline (KW6002) became the first A2A 
antagonist to undergo clinical trials for treatment of PD. In double-blind, placebo-controlled 
studies in levodopa-treated PD subjects with motor fluctuations, istradefylline-treated patients 
experienced a significant reduction in the amount of time spent in the off state compared to the 
placebo treated group (Hauser et al., 2003; Mizuno et al., 2010). Similar results have been 
obtained with the A2A antagonist preladenant (Hauser et al., 2011). Istradefylline is now used 
clinically in Japan for the treatment of Parkinson’s disease. 
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SSRIs for the Treatment of Depression in PD Patients  
While Parkinsonism is primarily characterized by the generation of the cardinal motor 
symptoms, patients with PD also suffer from a variety of significant non-motor symptoms, 
including autonomic dysfunction, sensory abnormalities, gastrointestinal issues, sleep disorders, 
and neuropsychiatric disturbances (Chaudhuri et al., 2006; Ostrem and Galifianakis, 2010; 
Barone, 2011). Neuropsychiatric symptoms are common even in the earliest stages of the 
disease, and can considerably affect the daily functioning and overall quality of life of PD 
patients (Chaudhuri et al., 2006; Aarsland et al, 2009; Barone, 2011). Depression, in particular, 
has been identified as the most significant predictor of health-related quality of life in PD 
(Schrag et al., 2000; Chaudhuri et al., 2006; Chen and Marsh, 2013), and systematic review and 
analysis suggest that 35-40% of patients with PD also experience clinically significant symptoms 
of depression (Slaughter et al, 2001; Aarsland et al, 2009).  
Selective serotonin reuptake inhibitors (SSRIs) are prescribed more often than any other 
class of antidepressants for PD patients (Vaswani et al, 2003; Veazey et al, 2005; Aarsland et al, 
2009; Chen and Marsh, 2013; Schreiber and Thompson, 2013). Yet controlled clinical trials, 
meta-analyses, and systematic review collectively suggest that SSRIs are no more effective than 
placebo in treating depression in the context of PD (Skapinakis et al, 2010; Aarsland et al, 2009). 
Furthermore, SSRI administration has been associated with a number of motor side-effects, and 
may be implicated in increased motor disability in PD patients (Leo, 1996; Richard et al, 1997; 
Gerber and Lynd, 1998; Govoni et al, 2001; Vaswani et al, 2003; Veazey et al, 2005; Aarsland et 
al, 2009). There are presently more than 100 published reports of “extrapyramidal” symptoms 
(e.g. dystonia, akathisia, dyskinesia, and Parkinsonism, including tremor) associated with SSRI 
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treatment; fluoxetine (Prozac; FLX) has been implicated in the majority of these reports 
(Madhusoodanan et al, 2010).  
FLX primarily functions as an inhibitor of the serotonin (5-HT) transporter, preventing 
uptake of 5-HT and ultimately resulting in increased activation of a variety of 5-HT receptors, 
including the 5-HT1A, 5-HT2A, and 5-HT2C receptors found throughout the striatum (Nutt et al, 
1999; Alex and Pehek, 2007; More et al, 2014). Interactions between 5-HT and DA 
neurotransmission are strongly implicated in the generation of motor dysfunctions associated 
with FLX treatment (Morelli et al, 2011), as DA release and metabolite production are inhibited 
by increased synaptic levels of 5-HT (Govoni et al, 2001; Morelli et al, 2011). Activation of 5-
HT2C receptors has been linked to decreased DA synthesis, neural activity and release in the 
nigrostriatal and mesolimbic DA pathways (Alex and Pehek, 2007; More et al, 2014). In rodent 
models, FLX administration has been shown to potentiate haloperidol-induced catalepsy and 
bradykinesia in a dose-dependent manner (Tatara et al, 2012; More et al, 2014).  
 
Cortical and Subthalamic Oscillatory Activity in PD Patients  
 Exaggerated neuronal synchrony has been observed within the basal ganglia of patients 
with PD, indicated by increases in oscillatory activity in the discharge of single neurons, 
increased amplitude of local field potentials (LFPs), and increased coherence of LFP signals 
across different basal ganglia structures in patients undergoing surgical procedures (Brown et al., 
2001; Brown and Williams, 2005; Hammond et al., 2007; Gale et al., 2008). There is oscillatory 
activity at a wide range of frequencies within basal ganglia circuits, ranging from slow (< 2 Hz) 
oscillations to faster gamma frequency (30-80 Hz) oscillations (Pare et al., 1990; Brown, 2003).  
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The best-characterized oscillation frequency band in the basal ganglia of PD patients is the beta 
band (~15-30 Hz), as indicated by the LFP in basal ganglia structures, as well as cortical 
electroencephalogram (EEG) and magnetoencephalography (MEG) (Brown et al., 2001; Priori et 
al., 2004; Hammond et al., 2007; Hirschmann et al., 2011; George et al., 2013; Oswal et al., 
2013). Increased oscillatory activity in the beta band has been observed in the subthalamic 
nucleus (STN) of PD patients, and it has been suggested that excessive synchrony in this 
frequency range contributes to deficits in motor control (Levy et al., 2002; Brown and Williams, 
2005; Kuhn et al., 2006). Increases in STN beta power can be observed in the LFP of PD patients 
off L-DOPA, which diminishes once L-DOPA treatment is reinstated (Brown et al., 2001; Levy 
et al., 2002; Priori et al., 2004; Brown and Williams, 2005). Furthermore, improvement in 
akinesia-rigidity as indicated by the Unified Parkinson’s Disease Rating Scale (UPDRS) in PD 
patients is highly correlated with reduction in STN beta band power (Kuhn et al., 2006). Thus, 
reduction in beta band oscillatory activity in the STN is thought to correlate with motor symptom 
improvement, particularly akinesia and rigidity, in PD patients (Levy et al., 2002; Kuhn et al., 
2006; Hammond et al., 2007). Consistent with human data, rats with unilateral 6-OHDA lesions 
to the substantia nigra pars compacta (SNc) show increased beta-frequency oscillatory activity in 
LFPs recorded from the STN, which diminish after administration of the dopamine agonist 
apomorphine (Sharott et al., 2005; Mallet et al., 2008).  
While the literature supports a link between increased power in the beta band frequency 
range in the cortex and basal ganglia and the development of akinesia/rigidity, beta band activity 
has not been shown to correlate with the severity of resting tremor (Kuhn et al., 2005; Kuhn et 
al., 2006; Hammond et al., 2007; Oswal et al., 2013). Rather, the development of tremor in PD 
patients has been shown to be associated with the emergence of oscillations in the tremor 
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frequency range (3-7 Hz) in the cortex and basal ganglia (Timmerman et al., 2003; Reck et al., 
2009; Hirschmann et al., 2013; Oswal et al., 2013). Timmerman et al., 2003 report a strong 
coherence between the electromyography (EMG) of forearm muscles and activity in the 
contralateral primary motor cortex (M1), at tremor (3-7 Hz) and double tremor frequency (7-13 
Hz) in PD patients off medication. A similar pattern of activity has been observed in the STN. In 
African green monkeys treated with MPTP, the development of resting tremor was associated 
with the emergence of oscillations at tremor frequency and double tremor frequency in the STN 
(Bergman et al., 1994). Power spectra of STN LFPs in PD patients reveal peaks at tremor 
frequency and tremor harmonics, as well as significant coherence between STN LFPs and EMG 
activity at tremor frequency (Brown et al., 2001; Levy et al., 2000; Liu et al., 2002; Wang et al., 
2005; Reck et al., 2009). Furthermore, Hirschmann et al. 2013 simultaneously recorded STN 
LFPs, magnetoencephalography (MEG), and the EMG of forearm muscles in PD patients off 
medication, and report a positive correlation between tremor-associated increase in STN-cortex 
coherence and tremor-associated increase in muscle activity. Together, these studies show that 
cortical and STN power and coherence at tremor frequency increases with the manifestation of 
tremor.  	  
Present Work 
 The present set of experiments seeks to characterize aspects of the instigation and 
treatment of Parkinsonian resting tremor using the tremulous jaw movement model. 
Experimental group 1 examines the ability of the galantamine to induce TJMs in mice, as it has 
yet to be evaluated if administration of an anticholinesterase induces TJMs in mice. 
Experimental groups 2 and 3 investigate the antiparkinsonian properties of MAO-B inhibitors by 
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evaluating behavioral and neurochemical changes. The interaction between dopamine and 
serotonin neurotransmission that underlies the exacerbation of Parkinsonian motor symptoms 
after SSRI administration will be addressed in experimental group 4. Finally, experimental group 
5 will employ electrophysiological techniques to investigate the neural circuitry that underlies 
tremorogenesis by examining the relationship between the development of tremor and oscillatory 
activity in the primary motor cortex and subthalamic nucleus in rats.  
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Chapter 2: Induction of oral tremor in mice by the acetylcholinesterase inhibitor 
galantamine: Reversal with adenosine A2A antagonism 
2.1 Introduction 
 Parkinsonism is a family of motor disorders characterized by four cardinal motor 
symptoms: resting tremor, akinesia, bradykinesia, and rigidity. Idiopathic Parkinson’s disease is 
the most common form of Parkinsonism, while drug administration is the second most common 
cause (Alvarez et al., 2007; Shulman et al., 2011). Drug-induced Parkinsonism (DIP) can result 
from administration of pharmacological agents that reduce DA transmission, such as DA 
antagonists and DA depleting agents (Marsden et al., 1975; McEvoy, 1983; Arbaizar et al., 
2008). Thus, DIP has been associated with the administration of a variety of typical and atypical 
antipsychotics, antiemetics, antihypertensives, gastrointestinal prokinetics, and antivertigo agents 
(Mena and de Yébenes, 2006; Alvarez et al., 2007; Shin and Chung, 2012). Additionally, several 
clinical studies report an induction or worsening of parkinsonian motor symptoms after 
cholinomimetic administration. Anticholinesterases such as tacrine, donepezil, rivastigmine and 
galantamine are effective in treating cognitive dysfunction in patients with Alzheimer’s disease 
(AD), but have been shown to induce Parkinsonian symptoms, including tremor, as a side effect 
(Ott and Lannon, 1992; Shea et al., 1998; Arai, 2000; Aarsland et al., 2003; Emre et al., 2004; 
Litvinenko et al., 2008; Song et al., 2008; Grace et al., 2009; van Laar et al., 2010).  
 Parkinsonian resting tremor can be modeled in rats using the tremulous jaw movement 
(TJM) model. TJMs are defined as rapid, repetitive, vertical deflections of the lower jaw that 
resemble chewing but are not directed at any particular stimulus (Salamone et al., 1998).  These 
movements can be induced by many of the same pharmacological agents that have been shown 
to produce DIP in humans, including DA antagonists (Steinpreis et al., 1993; Salamone et al., 
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1998; Correa et al., 2004; Ishiwari et al., 2005; Salamone et al., 2008a; Betz et al., 2009) and DA 
depleting agents (Baskin and Salamone, 1993; Salamone and Baskin, 1996; Podurgiel et al., 
2013a). Alterations in acetylcholine (ACh) transmission via administration of muscarinic 
agonists and anticholinesterases also can regulate the production of TJMs (Salamone et al. 1986; 
Baskin et al., 1994; Salamone et al., 1998; Miwa et al., 2008, 2009; Collins et al., 2010; Collins 
et al., 2011). In humans, Parkinsonian resting tremor occurs in the frequency range of 3-7 Hz, 
which is distinct from dyskinesias (1-2 Hz), essential tremor (8 Hz), and postural tremors (8-12 
Hz) (Findley et al., 1981, Marsden, 1984; Deuschl et al., 1996, 2000; Collins-Praino et al. 2012). 
In rats, it also has been reported that TJMs occur predominately in the 3-7.5 Hz frequency range, 
consistent with the frequency range characteristic of Parkinsonian resting tremor (Salamone et al. 
1998; Finn et al., 1998; Cousins et al., 1998; Ishiwari et al., 2005; Collins et al., 2011). 
Moreover, TJMs in rats can be attenuated using antiparkinsonian agents including L-DOPA 
(Cousins and Salamone, 1996; Cousins et al. 1998) DA agonists (Baskin and Salamone, 1993; 
Cousins et al., 1998; Salamone et al., 2005), muscarinic antagonists (Steinpreis et al., 1993; 
Cousins et al., 1998; Betz et al., 2009), and adenosine A2A antagonists (Correa et al. 2004; 
Salamone et al., 2008a; Betz et al., 2009; Collins et al., 2010, 2011, 2012; Salamone et al., 2013; 
Santerre et al., 2012;  Podurgiel et al., 2013a).  
 In order to provide cross-species comparisons, researchers have been expanding the TJM 
to mice. TJMs in mice were shown to be induced after administration of the muscarinic agonist 
pilocarpine and the DA-depleting agent tetrabenazine, and both pilocarpine and tetrabenazine-
induced TJMs can be attenuated by coadministration of the adenosine A2A antagonist MSX-3 or 
by conditional neural knockout of the adenosine A2A receptor (Salamone et al., 2013; Podurgiel 
et al., 2013a). However, it has yet to be determined if administration of an anticholinesterase 
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induces TJMs in mice. The anticholinesterase galantamine has been reported to induce or worsen 
tremor in human patients (Aarsland et al., 2003; Litvinenko et al., 2008; Grace et al., 2009) and 
induces TJMs in rats (Collins et al., 2011; Podurgiel et al., 2013b). The present study sought to 
develop a mouse model of cholinomimetic-induced TJMs using the anticholinesterase 
galantamine. The first experiment examined the ability of galantamine to induce TJMs in mice, 
and the second experiment assessed the ability of the adenosine A2A antagonist MSX-3 to 
attenuate galantamine-induced TJMs. The final experiment employed freeze-frame video 
analyses to evaluate the local frequency of TJMs induced by galantamine, as well as the 
tremorolytic effects of MSX-3. This experiment was conducted to determine if galantamine- 
induced TJMs would occur predominantly in the 3-7.5 Hz frequency range, and also if co-
administration of MSX-3 would alter the local frequency characteristics of the of galantamine-
induced TJMs.   
 
2.2 Materials and Methods 
 Animals 
Male C57BL/6J mice (N=37) weighed 35-45 g during the course of the experiment and 
had ad libitum access to lab chow and water (Jackson Laboratories, Bar Harbor, ME). They were 
group-housed in a colony that was maintained at approximately 23°C and had a 12-hour 
light/dark cycle (lights on at 0700 hrs). These studies were conducted according to University of 
Connecticut and NIH guidelines for animal care and use. 
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Drug Treatment Procedures and Dose Selection 
 The acetylcholinesterase inhibitor galantamine hydrobromide ((4aS,6R,8aS) 
5,6,9,10,11,12-hexahydro-3-methoxy-11-methyl-4aH-[1]benzofuro[3a,3,2-ef] [2] benzazepin-6-
ol) was obtained from Tocris Bioscience (Bristol, UK). Galantamine was dissolved in 0.9% 
saline. MSX-3 ((E)-phosphoric acid mono-[3-[8-[2-(3-methoxyphenyl)vinyl]-7-methyl-2,6-
dioxo-1-prop-2-ynyl-1,2,6,7-tetrahydropurin-3-yl]propyl] ester), the adenosine A2A antagonist, 
was synthesized at the Pharmazeutisches Institut Universität Bonn; Bonn, Germany (see 
Hockemeyer et al., 2004). MSX-3 was dissolved in 0.9% saline. The pH of the MSX-3 solution 
was adjusted by adding 1.0 N NaOH until the drug was completely in solution after conversion 
to its disodium salt (pH 7.1 – 7.7). MSX-3 is a prodrug that is converted into the active 
adenosine A2A antagonist, MSX-2, in vivo. The doses of galantamine (0.5, 1.0, 1.5, 2.0, 2.5 
mg/kg) were selected based on extensive pilot studies, and doses of MSX-3 (2.5, 5.0, 10.0 
mg/kg) were chosen based on previous data from our laboratory (Salamone et al., 2013). 
 
Behavioral Procedure: Tremulous Jaw Movements 
Observations of mice took place in a 11.5 × 9.5 × 7.5 cm clear glass chamber with a wire 
mesh floor, which was elevated 26 cm from the table top. Tremulous jaw movements were 
defined as rapid vertical deflections of the lower jaw that resembled chewing but were not 
directed at any particular stimulus. Each individual deflection of the jaw was recorded using a 
mechanical hand counter by a trained observer, who was blind to the experimental condition of 
the mouse being observed. Separate studies with two observers demonstrated an inter-rater 
reliability of r=0.98 (p<0.001) using these methods in mice. 
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Experiments 
Experiment 1: Ability of galantamine to induce tremulous jaw movements in mice  
A group of 15 mice was used to assess the ability of galantamine to induce TJMs. All 
mice received IP injections of either 1.0 ml/kg saline (vehicle) or 0.5, 1.0, 1.5, 2.0, or 2.5 mg/kg 
galantamine in a within-groups design, with all mice receiving all drug treatments in a randomly 
varied order (one treatment per week; no treatment sequences repeated). Twenty minutes after IP 
injection, the mice were placed in the chamber and allowed to habituate for five minutes. 
Following the habituation period, TJMs were counted for fifteen minutes, with the observation 
period divided into three five-minute epochs. 
 
Experiment 2: Ability of the adenosine A2A antagonist MSX-3 to attenuate tremulous jaw 
movements induced by galantamine 
A group of 10 mice was used to assess the effect of administration of the adenosine A2A 
antagonist MSX-3 on TJMs induced by 2.5 mg/kg galantamine. A within-groups design was 
utilized for this study, with all mice receiving all drug treatments in a randomly varied order (one 
treatment per week; no treatment sequences repeated). On the test day each week, each mouse 
received an IP injection of either 1.0 ml/kg saline (vehicle) or 2.5 mg/kg galantamine. After 5 
minutes, mice received an IP injection of either 1.0 ml/kg saline (vehicle) or 2.5, 5.0, or 10.0 
mg/kg MSX-3. Fifteen minutes after the second injection, mice were placed in the observation 
chamber and allowed to habituate for 5 minutes. TJMs were then counted for 15 minutes, with 
the observation period divided into three five-minute epochs. 
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Experiment 3: Freeze-frame video analysis of the local frequency of tremulous jaw movements 
induced by galantamine 
A total of 12 mice were used to examine the local frequency of galantamine-induced 
TJMs and the local frequency of TJMs after coadministration of galantamine and MSX-3. A 
within-groups design was utilized for this study, with all mice receiving all drug treatments in a 
randomly varied order (one treatment per week; no treatment sequences repeated). On the test 
day each week, each mouse received an IP injection of 2.5 mg/kg galantamine. After 5 minutes, 
mice received an IP injection of either 1.0 ml/kg saline (vehicle) or 10.0 mg/kg MSX-3. After 15 
minutes, mice were placed in a flat bottomed mouse restrainer (myNeuroLab.com, Richmond, 
IL) so that a consistent view of the orofacial area could be achieved. After habituating for 5 
minutes, each mouse was recorded for 15 minutes (using a Cannon PowerShot SX120 digital 
camera, in video mode.) The sections of video were subjected to a freeze-frame analysis (1 
frame=1/30 s), in which the observer went frame-by-frame through each burst of jaw movements 
(i.e. each group of at least two jaw movements that were within 1.0 s of each other). The 
observer recorded the inter-movement interval for each pair of jaw movements within bursts, 
which was defined as the number of frames between each point at which the jaw was fully open 
during successive jaw movements. This information was used to determine the local frequency 
within bursts of jaw movements.  
  
Data Analyses 
 The data for experiments 1 and 2 were analyzed using a repeated measures analysis of 
variance (ANOVA). A computerized statistical program (SPSS 21.0 for Windows) was used to 
perform these analyses. Average TJMs per five-minute observation period were calculated and 
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used in the ANOVA calculations. When there was a significant ANOVA in experiments 1 and 2, 
planned comparisons using the overall error term were used to assess the differences between 
each dose and the control condition (the number of comparisons was restricted to the number of 
treatments minus one; Keppel, 1991). The video files from experiment 3 were analyzed using 
Adobe Premiere CS5.5 for Windows, which allowed freeze-frame analysis in a frame-by-frame 
sequence (1 frame = 1/30 s). The data for experiment 3 were analyzed by calculating a relative 
frequency distribution (i.e., each bin represented as percent of total inter movement intervals), 
and the interaction term from the repeated measures factorial ANOVA was used to determine if 
the relative distributions of inter-movement times differed between the galantamine and the 
galantamine plus MSX-3 conditions. 
 
2.3 Results 
Experiment 1: Ability of galantamine to induce tremulous jaw movements in mice 
Repeated measures ANOVA revealed a significant overall effect of galantamine on TJMs 
(Figure 2.1; F(5,70) = 4.271; p<0.05). The 1.5, 2.0, and 2.5 mg/kg dose of galantamine 
significantly induced TJMs (planned comparisons, p< 0.05) compared to vehicle control. 
 
Experiment 2: Ability of the adenosine A2A antagonist MSX-3 to attenuate tremulous jaw 
movements induced by galantamine 
As shown in Figure 2.2, there was a significant overall effect of MSX-3 co-
administration on galantamine-induced TJMs (F(4,36) = 6.187; p<0.05). The 2.5 mg/kg dose of 
galantamine significantly induced TJMs compared to vehicle control (planned comparisons, 
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p<0.05), and all doses of MSX-3 (2.5, 5.0, and 10.0 mg/kg) significantly attenuated galantamine-
induced TJMs (planned comparisons, p<0.05). 
 
Experiment 3: Freeze-frame video analysis of the local frequency of tremulous jaw movements 
induced by galantamine 
 Analysis of the videos showed that there were 48.2 + 6.5 identified TJMs shown by rats 
tested in the galantamine plus vehicle condition, and 31.8 + 7.9 in the galantamine plus MSX-3 
condition.  Analysis with the matched-pair t-test revealed that MSX-3 significantly reduced the 
number of TJMs in galantamine-treated mice relative to galantamine alone (t= 2.97, df = 4, p < 
0.05).  Figure 2.3 shows the relative frequency distributions of inter movement times for the 
galantamine plus saline and galantamine plus MSX-3 conditions. Repeated measures factorial 
ANOVA revealed that there was a significant overall difference across inter-movement interval 
bins (F(29,232) = 67.7; p<0.0001) and a significant interval bin x drug condition interaction 
(F(29,232) = 1.58; p < 0.05).  The significant interaction indicates that the relative distribution of 
inter-movement intervals in galantamine-treated rats was altered by co-administration of MSX-3. 
Four of five rats treated with galantamine plus saline showed a peak number of inter-movement 
intervals in bin 5, while four of five rats treated with galantamine plus MSX-3 showed a peak in 
bin 6. 
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Figure 2.1: Effects of different doses of galantamine (IP) on tremulous jaw movements. Mean (± 
SEM) number of jaw movements (per 5 min period) in mice treated with either saline vehicle or 
galantamine. *significant difference from vehicle control (p < 0.05)  
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Figure 2.2: Effect of adenosine A2A antagonism on galantamine (2.5 mg/kg) induced TJMs. 
Mean ( + SEM) number of jaw movements (per 5 min period) in mice treated with vehicle, 
galantamine plus vehicle (Gal/Veh), and galantamine plus various doses (2.5-10.0 mg/kg) of 
MSX-3. # significant difference from vehicle; *significant difference from galantamine plus 
vehicle control (p < 0.05) 
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Figure 2.3:  Results of the freeze-frame video analysis, showing the relative frequency 
distribution of inter-movement intervals across several time bins. The mean (± SEM) number of 
inter-movement intervals, expressed as a percent of total, is shown for each frequency bin, for 
mice treated with galantamine plus saline vs. galantamine plus MSX-3. There was a significant 
interval bin x drug treatment interaction (see text for details). 
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Chapter 3: Tremorolytic effects of safinamide in animal models of drug induced 
parkinsonian tremor  
Published; Podurgiel et al., 2013  
3.1 Introduction 
In idiopathic Parkinson’s disease, neurodegenerative processes that deplete striatal 
dopamine (DA) result in the development of motor symptoms including akinesia, bradykinesia, 
rigidity and tremor (Bernheimer et al., 1973).  In addition, several classes of drugs are known to 
induce parkinsonian symptoms in humans. Administration of antipsychotic drugs that block DA 
receptors (e.g., haloperiodol, chlorpromazine, pimozide) or deplete striatal DA (e.g. reserpine or 
tetrabenazine) has been shown to induce parkinsonian motor symptoms (Marsden et al., 1975; 
McEvoy, 1983; Arbaizar et al., 2008). Furthermore, cholinomimetic drugs are known to be 
tremorogenic (Brimblecomb, 1975; Dronfield et al. 2000; Liston et al. 2004; Salamone et al. 
2001), and several clinical studies have reported that cholinomimetics can induce or exacerbate 
parkinsonian symptoms, including tremor, in humans (Aarsland et al. 2003; Arai, 2000; Bourke 
and Drukenbrod, 1998; Cabeza-Alvarez et al. 1999; Duvoisin, 1967; Gurevich et al. 2006; 
Iwasaki et al. 1988; Kao et al. 1993; Keltner, 1994; McSwain and Forman, 1995; Ott and 
Lannon, 1992; Shea et al. 1998; Song et al. 2008).  The most common treatment for idiopathic 
Parkinson’s disease is the DA precursor L-DOPA, but parkinsonian symptoms also are treated by 
a number of other dopaminergic and non-dopaminergic agents, including DA agonists, 
muscarinic acetylcholine antagonists (Aquilonius, 1980; McEvoy, 1983), and amantadine.  
Novel therapeutic approaches include adenosine A2A antagonists, gene therapies, and various 
surgical procedures intended to restore neurochemical balance in the basal ganglia circuitry 
(Salamone 2010; Hauber 2011). 
26 	  
Monoamine oxidase B (MAO-B) inhibitors have also been employed as a treatment for 
parkinsonism (Moussa et al. 2006; Onofrj et al. 2008; Schapira 2010). MAO-B is one of the key 
enzymes responsible for dopamine metabolism in the brain (Moussa et al. 2006). Selegiline and 
rasagiline are potent, irreversible MAO-B selective inhibitors that are presently available for the 
treatment of PD (Onofrj et al. 2008; Schapira 2010). Safinamide, ((S)-(+)-2-[4-(3-
fluorobenzyloxybenzylamino)pro-panamide]methanesulfonate (1:1 salt), is a water soluble, α-
aminoamide derivative with multiple actions (Marzo et al. 2004; Fariello 2007; Onofrj et al. 
2008; Schapira 2010; Stocchi 2012). Safinamide is a potent, highly selective and reversible 
inhibitor of MAO-B (Marzo et al. 2004; Fariello 2007; Onofrj et al. 2008 Schapira 2010; Stocchi 
2012). Additionally, safinamide reduces dopamine uptake, blocks voltage-dependent sodium 
channels, modulates N-type calcium channels, and reduces glutamate release (Marzo et al. 2004; 
Fariello 2007; Onofrj et al. 2008; Schapira 2010; Stocchi 2012). By doing so, animal studies 
have revealed that safinamide exerts neuroprotectant, anticonvulsant, and antiparkinsonian 
properties (Salvati et al. 1999; Fariello et al. 2000; Gregoire et al. 2010). Safinamide has an 
excellent therapeutic and safety margin and is currently in Phase III clinical trial development as 
an add-on therapy to levodopa or dopamine agonists for PD patients (Marzo et al. 2004; Onofrj 
et al. 2008; Schapira 2010; Stocchi 2012).  
Several animal models have been used to assess various motor functions related to 
parkinsonism (Avila et al. 2009; Castañeda et al. 2005; Pollack and Thomas, 2009). Although 
resting tremor is one of the cardinal symptoms of parkinsonism, relatively little information is 
known about the neural mechanisms underlying tremorogenesis or its treatment (Bergman and 
Deuschl et al. 2002; Deuschl et al. 2001; Fishman 2008; Binder et al. 2009), and research 
employing animal models of tremor also can contribute greatly to our understanding of the 
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neurochemical regulation of tremorogenesis (Miwa 2007; Salamone et al. 1998; Wilms et al. 
1999). For this reason, the present studies used the tremulous jaw movement model, which is a 
rodent model of parkinsonian tremor that has been extensively employed (Cenci et al. 2002; 
Cousins and Salamone, 1998; Ishiwari et al. 2005; Miwa et al. 2008, 2009; Rodriguez-Diaz et al. 
2001; Salamone et al. 1990, 1998, 2001, 2005, 2008a, 2008b; Simola et al. 2004, 2006; Vanover 
et al. 2008). These movements are defined as repetitive vertical deflections of the lower jaw that 
resemble chewing but are not directed at a particular stimulus (Salamone et al. 1998).  As shown 
by studies using videotape analyses or electromyographic methods, these movements occur 
largely within the 3-7 Hz frequency range that is characteristic of parkinsonian resting tremor 
(Cousins et al. 1998; Finn et al. 1997; Ishiwari et al. 2005; Mayorga et al. 1997), and can be 
induced by a number of conditions that parallel the neurochemistry of the pathology of 
parkinsonism, including striatal DA depletion, DA antagonism, anticholinesterases and 
muscarinic agonists (Baskin and Salamone, 1993; Betz et al. 2005; Cousins and Salamone 1998; 
Finn et al. 1997; Ishiwari et al. 2005; Jicha and Salamone 1991; Mayorga et al. 1997; Rodriguez-
Diaz et al. 2001; Salamone and Baskin, 1996; Salamone et al. 1990, 1998, 2005, 2008a;  
Steinpreis et al. 1993; Trevitt et al. 1998). Dopaminergic antiparkinsonian drugs such as 
apomorphine, L-DOPA, bromocriptine, pergolide, and ropinirole can reduce cholinomimetic-
induced tremulous jaw movements (Cousins et al., 1997; Salamone et al., 2005), and their 
potency for suppressing cholinomimetic-induced tremulous jaw movements is highly correlated 
(r = 0.88) with the clinical potency of these drugs for reducing parkinsonian tremor in humans 
(Salamone et al., 2005). Tremulous jaw movements are sensitive to several other classes of 
antiparkinsonian drugs, including muscarinic antagonists and adenosine A2A antagonists (Baskin 
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and Salamone 1993; Betz et al. 2007, 2009; Correa et al. 2004; Cousins et al. 1997; Salamone et 
al. 1998, 2008a; Simola et al. 2004, 2006; Steinpreis et al. 1993; Tronci et al. 2007). 
The present experiments examined the ability of safinamide to attenuate drug-induced 
tremulous jaw movements in rats. Because cholinomimetics are well known tremorogenic agents 
(Brimblecombe 1975; Salamone et al. 2001; Collins-Praino et al. 2011), the first two 
experiments will employ cholinomimetics that are known to induce tremulous jaw movements in 
order to assess the effects of safinamide. The first experiment assessed the ability of safinamide 
to reverse tremulous jaw movements induced by the anticholinesterase galantamine (Collins et 
al. 2011). The second experiment examined the ability of safinamide to attenuate tremulous jaw 
movements induced by the muscarinic agonist pilocarpine (Collins et al. 2010a). The final 
experiment studied the ability of safinamide to reverse the effects of the DA D2 antagonist 
pimozide on tremulous jaw movements and locomotor suppression, under the same conditions 
used previously for the assessment of other antiparkinsonian agents (Salamone et al. 2008a). 
These conditions (i.e., repeated administration of 1.0 mg/kg pimozide) were optimized for 
induction of tremulous jaw movements (Ishiwari et al. 2005; Salamone et al. 2008a), but also 
allow for assessment of locomotion. It was hypothesized that safinamide would be able to 
reverse the tremorogenic effects of galantamine, pilocarpine, and pimozide.  
 
3.2 Materials and Methods 
Animals 
A total of 118 adult male Sprague Dawley rats (Harlan Sprague Dawley, Indianapolis, 
IN) with no prior drug experience were used in the present experiments. The rats weighed 350-
450 g during the course of the experiment and had ad libitum access to lab chow and water. They 
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were group-housed in a colony that was maintained at approximately 23°C and had a 12-hour 
light/dark cycle (lights on at 0700 hrs). These studies were conducted according to University of 
Connecticut and NIH guidelines for animal care and use. 
 
Drug Treatment Procedures and Dose Selection 
Galantamine hydrobromide was obtained from Tocris Bioscience (Bristol, UK) and 
dissolved in 0.9% saline. Pilocarpine and pimozide were purchased from Sigma Aldrich 
Chemical (St. Louis, MO). Pilocarprine was dissolved in 0.9% saline, and pimozide was 
dissolved in a 0.3% tartaric acid solution (final pH = 4.0). Safinamide, (S)-(+)-2-[4-(3-
fluorobenzyloxybenzylamino)pro-panamide]methanesulfonate (1:1 salt) is a water soluble, α-
aminoamide derivative. Safinamide was obtained from Merck Serono International S.A. 
(Geneva, Switzerland) and was dissolved in 0.9% saline, which was also used as the vehicle 
control. An acute dose of 3.0 mg/kg (IP) galantamine or 0.5 mg/kg (IP) pilocarpine was used for 
the studies examining galantamine or pilocarpine-induced tremulous jaw movements. The 
selection of these doses was based on previously published experiments showing induction of 
jaw movements at these doses (Collins et al. 2010a, Collins-Praino et al. 2011a). Subchronic 1.0 
mg/kg (IP) pimozide treatment was used for the study examining tremulous jaw movements and 
locomotion. This treatment procedure was based upon previously published experiments 
showing induction of jaw movements at this dose (Ishiwari et al. 2005; Betz et al., 2007, 2009; 
Salamone et al. 2008a; Collins et al. 2010b). Subchronic 1.0 mg/kg (IP) pimozide treatment is 
optimized for the production of jaw movement activity and also allows for the parallel 
assessment of locomotion. The procedure of screening animals by assessing them for tremulous 
jaw movements the day before the drug challenge day was the same as that used in previous 
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studies (Ishiwari et al. 2005; Salamone et al. 2008a; Collins et al. 2010b). This was done in order 
to ensure a robust jaw movement response on the drug challenge day. None of the animals failed 
to show a substantial jaw movement response to pimozide on day 7. The doses of safinamide 
chosen were based upon extensive pilot work.  
Behavioral Procedures 
 Tremulous jaw movements. Observations of rats took place in a 30 × 30 × 30 cm clear 
Plexiglas chamber with a wire mesh floor, which was elevated 42 cm from the table top. This 
allowed for the viewing of the animal from several angles, including underneath. Tremulous jaw 
movements were defined as rapid vertical deflections of the lower jaw that resembled chewing 
but were not directed at any particular stimulus (Salamone et al. 1998). Each individual 
deflection of the jaw was recorded using a mechanical hand counter by a trained observer, who 
was blind to the experimental condition of the rat being observed.  
 Locomotor activity. Locomotor activity was assessed by placing the rat into an automated 
activity chamber (28 cm X 28cm X 28 cm) enclosed in a sound-attenuating shell. The floor of 
the chamber was elevated 6 cm above the chamber bottom and was composed of two moveable 
wire-mesh panels, (25 cm x 12 cm), which were further divided into four quadrants by means of 
a central metal rod between the two panels. As the rat entered each quadrant, a slight vertical 
movement of the mesh panels closed a microswitch located outside of the locomotion chamber. 
This depression was detected and recorded by a computer program, written in MedPC, as a 
single activity count (Med Associates, Inc., Georgia, VT).  The locomotor activity session was 
30-min in length. These methods of measuring locomotion have been used previously to assess 
the effects of DA and antagonists on locomotion (Collins et al. 2010a; Salamone et al., 2008a). 
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Experiments 
Experiment 1: Ability of safinamide to reverse tremulous jaw movements induced by the 
anticholinesterase galantamine. 
A group of 7 rats was used to assess the effects of safinamide on the tremulous jaw 
movements induced by administration of 3.0 mg/kg galantamine. A within-groups design was 
used for this study, with all rats receiving all drug treatments in a randomly varied order (one 
treatment per week; no treatment sequences were repeated).  On test day each week, all rats 
received an IP injection of 3.0 mg/kg galantamine 30 min before the test session. Concurrently, 
each rat was given an IP injection of either 1.0 mL/kg saline or 0.312 mg/kg, 0.625 mg/kg, 1.25 
mg/kg, 2.5 mg/kg, 5.0 mg/kg, or 10.0 mg/kg safinamide (30 min before the test session). Twenty 
min after injections, rats were placed in the Plexiglas observation chamber and allowed 10 min to 
habituate, after which tremulous jaw movements were counted for 15 min, following the same 
procedure outlined above.  
 
Experiment 2: Ability of safinamide to reverse tremulous jaw movements induced by the 
muscarinic agonist pilocarpine. 
   A group of 14 rats was used to assess the effects of safinamide on the tremulous jaw 
movements induced by administration of 0.5 mg/kg pilocarpine. A within-groups design was 
used for this study, with all rats receiving all drug treatments in a randomly varied order (one 
treatment per week; no treatment sequences were repeated). On test day each week, all rats 
received an IP injection of 0.5 mg/kg pilocarpine 10 min before the test session. In addition, each 
rat received an IP injection of either 1.0 mL/kg saline or 0.312 mg/kg, 0.625 mg/kg, 1.25 mg/kg, 
2.5 mg/kg, 5.0 mg/kg, or 10.0 mg/kg safinamide 30 min before the test session. Immediately 
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after pilocarpine injections, rats were placed in the Plexiglas observation chamber and allowed 
10 min to habituate, after which tremulous jaw movements were counted for 15 min, following 
the same procedure outlined above.  
 
Experiment 3: Ability of safinamide to reverse tremulous jaw movements and locomotor 
suppression induced by subchronic administration of the DA D2 antagonist pimozide.   
A group of 97 rats was used to assess the effects of subchronic systemic injections of the 
DA D2 antagonist pimozide on tremulous jaw movements. One group of rats received repeated 
daily injections of vehicle, and also received vehicle injections on the test day. All other rats 
received an injection of 1.0 mg/kg pimozide IP for 8 consecutive days. On day 7 of the 
subchronic injections, rats were assessed for the induction of tremulous jaw movements in a five 
min period. Any rat that showed less than 15 tremulous jaw movements on day 7 was excluded 
from further testing. Three hrs and 30 min following their daily pimozide injection on day 8, rats 
received an IP injection of vehicle control or safinamide (saline vehicle control, 0.625 mg/kg, 
1.25 mg/kg, 2.5 mg/kg, 5.0 mg/kg, 10.0 mg/kg safinamide). Twenty minutes later, animals were 
placed in the Plexiglas observation chamber and allowed to habituate for 10 min.  After the 
habituation period, the number of jaw movements in a 15-min observation period was assessed 
as described above. Immediately after completion of the tremulous jaw movement test, 
locomotor activity was assessed in a 30-min session, using the procedure outlined above.   
 
Data Analyses 
Behavioral data for experiments 1 and 2 was analyzed using a repeated measures analysis 
of variance (ANOVA). Behavioral data for experiment 3 was analyzed using a between groups 
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analysis of variance (ANOVA). A computerized statistical program (SPSS 19.0 for Windows) 
was used to perform all analyses. When there was a significant ANOVA, planned comparisons 
using the overall error term were used to assess the differences between each dose and the 
control condition; the total number of comparisons was restricted to the number of treatments 
minus one (Keppel, 1991).  
 
3.3 Results 
Experiment 1: Ability of safinamide to reverse tremulous jaw movements induced by the 
anticholinesterase galantamine. 
Figure 3.1 shows the effects of systemic injections of safinamide on tremulous jaw 
movements induced by galantamine. Co-administration of safinamide produced a significant 
reduction in galantamine induced tremulous jaw movements. ANOVA revealed a significant 
overall treatment effect (F(6,36)= 3.54, p < 0.05).  Planned comparisons revealed that each dose 
of safinamide plus galantamine differed significantly from galantamine plus vehicle (p < 0.05). 
  
Experiment 2: Ability of safinamide to reverse tremulous jaw movements induced by the 
muscarinic agonist pilocarpine 
 Figure 3.2 shows the effects of systemic injections of safinamide on tremulous jaw 
movements induced by pilocarpine. Co-administration of safinamide produced a significant 
reduction in pilocarpine induced tremulous jaw movements. ANOVA revealed a significant 
overall treatment effect (F(6,78)= 2.51, p < 0.05. Planned comparisons revealed that three doses 
of safinamide (0.625 mg/kg, 5.0 mg/kg, 10.0 mg/kg) plus pilocarpine differed significantly from 
pilocarpine plus vehicle (p < 0.05).  
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Experiment 3: Ability of safinamide to reverse tremulous jaw movements and locomotor 
suppression induced by subchronic administration of the DA D2 antagonist pimozide. 
 Figure 3.3 shows the effects of systemic injections of safinamide on tremulous jaw 
movements induced by pimozide. Co-administration of safinamide produced a significant 
reduction in pimozide induced tremulous jaw movements. ANOVA revealed a significant overall 
treatment effect (F(6,90)= 7.6, p < 0.05; pimozide significantly induced tremulous jaw 
movements relative to Veh/Veh (p < 0.05). Planned comparisons revealed that three doses of 
safinamide (1.25 mg/kg, 5.0 mg/kg, 10.0 mg/kg) plus pimozide differed significantly from 
pimozide plus vehicle (p < 0.05). There was an overall significant drug treatment effect 
(F(6,87)= 20.3, p < 0.001). Pimozide significantly reduced locomotor activity counts relative to 
Veh/Veh (p < 0.05).  However, there were no significant effects of safinamide on pimozide-
induced suppression of locomotion.  
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Figure 3.1: Effect of safinamide on the tremulous jaw movements induced by 3.0 mg/kg of the 
acetylcholinesterase inhibitor galantamine. Mean (+ SEM) number of jaw movements in rats 
treated with galantamine plus vehicle (Veh), and galantamine plus various doses (0.3125-10.0 
mg/kg IP) of safinamide. *significant difference from galantamine plus vehicle (Veh) control (p 
< 0.05) 
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Figure 3.2: Effect of safinamide on the tremulous jaw movements induced by 0.5 mg/kg of the 
muscarinic acetylcholine receptor agonist pilocarpine. Mean (+ SEM) number of jaw movements 
in rats treated with pilocarpine plus vehicle (Veh), and pilocarpine plus various doses (0.3125-
10.0 mg/kg IP) of safinamide. *significant difference from pilocarpine plus vehicle (Veh) control 
(p < 0.05) 
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Figure 3.3: Effect of safinamide on pimozide-induced tremulous jaw movements. Mean (+ 
SEM) number of individual jaw movements (per 5 min observation period) after injection of 
tartaric acid vehicle plus1.0 mg/kg pimozide or pimozide plus various IP doses of safinamide.    
* p < 0.05, different from vehicle plus pimozide. 
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Chapter 4: MAO-B inhibition attenuates Parkinsonism induced by the VMAT-2 inhibitor 
tetrabenazine 
4.1 Introduction  
Idiopathic Parkinson’s disease (PD) results from the death of dopamine (DA) producing 
cell bodies in the substantia nigra pars compacta, which causes the degeneration of the 
nigrostriatal pathway and depletion of DA in striatal areas (Hornykiwicz, 1973). Idiopathic PD is 
one member of a broader family of motor disorders known as Parkinsonism, the members of 
which share five cardinal motor symptoms: resting tremor, akinesia, bradykinesia, rigidity, and 
postural instability (Marsden et al, 1975; Ostrem and Galifianakis, 2010). While idiopathic PD is 
the most common cause of Parkinsonism, administration of pharmacological agents that decrease 
DA or increase acetylcholine (ACh) neurotransmission is the second most common cause 
(Ostrem and Galifianakis, 2010). Rodent models are a valuable tool for studying Parkinsonism, 
and several behavioral paradigms exist to evaluate the motor symptoms. Catalepsy and 
locomotor activity can be used to model symptoms such as akinesia and bradykinesia, and the 
tremulous jaw movement (TJM) model is widely used for studying parkinsonian tremor. TJMs, 
defined as “vertical deflections of the lower jaw that resemble chewing but are not directed at 
any particular stimulus” (Salamone et al., 1998) are induced in rats by many of the same 
pharmacological agents that are responsible for drug-induced Parkinsonism in humans, including 
dopamine (DA) depleting agents (Baskin and Salamone, 1993; Podurgiel et al., 2013a), DA 
antagonists (Steinpreis et al., 1993; Ishiwari et al., 2005) and cholinomimetics (Salamone et al. 
1986; Collins et al., 2011). TJMs have a local frequency of 3-7.5 Hz, which parallels the 
frequency range characteristic of resting tremor in humans (Salamone et al. 1996, 1998; Finn et 
al., 1997; Mayora et al., 1997; Cousins et al., 1998; Ishiwari et al., 2005; Collins et al., 2011), 
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and can be attenuated by coadministration of antiparkinsonian agents (Baskin and Salamone, 
1993; Steinpreis et al., 1993; Cousins and Salamone, 1996; Cousins et al. 1997; Mayorga et al., 
1997; Correa et al. 2004; Salamone et al., 2005; Betz et al., 2009, Salamone et al., 2008; Collins 
et al., 2010a, 2011, 2012; Santerre et al., 2012; Podurgiel et al., 2013a, 2013b).  
Tetrabenazine (TBZ) is a reversible and selective inhibitor of the type-2 vesicular 
monoamine transporter (VMAT-2; Erickson et al., 1996), which was approved by the Food and 
Drug Administration in 2008 for treatment of chorea associated with Huntington’s disease (HD) 
(de Tommaso et al., 2011). TBZ blocks vesicular storage and depletes monoamines, but has its 
greatest effects upon DA neurons, and exhibits its highest binding density in DA-rich areas of the 
brain including the caudate/putamen, substantia nigra pars compacta, and nucleus accumbens 
(Pettibone et al., 1984a, 1984b; Pearson and Reynolds, 1988; Thibaut et al., 1995; Tanra et al., 
1995; German et al., 2000). Research with humans has indicated that TBZ is effective at treating 
HD-associated chorea in both the short and long-term (Kenney et al., 2007a,b; Frank, 2009; Poon 
et al., 2010; de Tommaso et al., 2011; Chen et al., 2012), but also can induce adverse events, 
including drowsiness and depression, as well as Parkinsonian motor symptoms (Kenney et al., 
2007a; Frank, 2009).  
Our laboratory has recently established a pharmacological rodent model of Parkinsonism 
using TBZ (Podurgiel et al., 2013a). When administered to rats, TBZ induces TJMs, catalepsy, 
and locomotor suppression, and coadministration of the adenosine A2A antagonist MSX-3, a 
putative antiparkinsonian agent, attenuates these motor deficits (Podurgiel et al., 2013a). 
Furthermore, MSX-3 reverses TBZ-induced c-Fos expression in the ventrolateral striatum (VLS) 
(Podurgiel et al., 2013a), the striatal subregion associated with the production TJMs (Salamone 
et al., 1990; Jicha and Salamone, 1991). Since it is critical to validate animal models, and MSX-3 
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has been the only antiparkinsonian agent used to attenuate TBZ-induced Parkinsonism, this study 
examined the behavioral and neurochemical effects of administration of the well-established 
antiparkinsonian agent deprenyl (Selegiline) on TBZ-induced Parkinsonism. Deprenyl is a 
potent, irreversible, selective inhibitor of monoamine oxidase type B (MAO-B), one of the key 
enzymes responsible for dopamine metabolism in the brain (Youdim and Bakhle, 2006). 
Deprenyl has been employed for over 30 years for the treatment of motor symptoms in early and 
late stage PD (Schapira et al., 2011; Riederer P, Laux G, 2011; Fabbrini et al., 2012). The present 
study examined the ability of deprenyl to attenuate TBZ-induced TJMs, and assessed 
extracellular DA levels in the VLS after administration of TBZ alone and coadministration of 
TBZ and deprenyl.  
 
4.2 Materials and Methods 
Animals 
Adult male Sprague Dawley rats (N=26) weighing 350-450g during the course of the 
experiment had ad libitum access to lab chow and water (Harlan Laboratories, Indianapolis, IN). 
They were pair-housed in a colony that was maintained at approximately 23°C and had a 12-hour 
light/dark cycle (lights on at 0700 hrs). These studies were conducted according to University of 
Connecticut and NIH guidelines for animal care and use. 
 
Drug Treatment Procedures and Dose Selection 
Tetrabenazine was purchased from Tocris Bioscience (Bristol, UK) and dissolved in a 
vehicle solution of 0.9% saline (80%) and dimethylsulfoxide (DMSO) (20%). Ten µl 
hydrochloric acid (HCl)/mL volume was then added to get the drug completely into solution. 
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Deprenyl was purchased from Tocris Bioscience (Bristol, UK) and dissolved in 0.9% saline. The 
dose of tetrabenazine (2.0 mg/kg) used in these experiments was based on data from Podurgiel et 
al., 2013, showing this dose significantly induces TJMs. Doses of deprenyl were based on 
extensive pilot work.  
 
Behavioral Procedure: Tremulous Jaw Movements  
Observations of rats took place in a 30 × 30 × 30 cm clear Plexiglas chamber with a wire 
mesh floor, which was elevated 42 cm from the table top. This allowed for the viewing of the 
animal from several angles, including underneath. TJMs were defined as rapid vertical 
deflections of the lower jaw that resembled chewing but were not directed at any particular 
stimulus (Salamone et al, 1998). Each individual deflection of the jaw was recorded using a 
mechanical hand counter by a trained observer, who was blind to the experimental condition of 
the rat being observed. Separate studies with two observers demonstrated an inter-rater reliability 
of r = 0.999 (p < 0.01) using these methods. 
 
Surgical Procedures 
Before surgery, rats were anesthetized with a 1.0 ml/kg IP injection of a cocktail 
solution containing 10.0 ml of 100 mg/mL ketamine plus 0.75 ml of 20.0 mg/ml xylazine (both 
from Phoenix Scientific, Inc., St. Joseph, MO, USA). Rats were placed in a stereotaxic frame 
(Kopf, Tujunga, CA, USA; incisor bar 5.0 mm above interaural line), and received unilateral 
implantations of a 10.0 mm probe guide cannula (Bioanalytical Systems, Indianapolis, IN, USA). 
The tips of the guide cannulae were implanted intro the ventrolateral striatum (AP: +1.4 mm, 
ML: ±3.8 mm, DV: −5.2 mm from bregma; counterbalanced for left vs. right) and were secured 
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to the skull with stainless steel screws and cement. Stainless steel stylets were inserted into the 
guide cannulae to maintain patency. Following surgery, animals were housed in separate cages 
and allowed 7 days post-surgical recovery. 
 
DA Microdialysis and HPLC 
Rats with implanted cannulae were placed in Plexiglas chambers (28 x 28 x 23 cm) the 
day before sampling for 8 hours of habituation with the infusion pumps running. The following 
day, the probe was inserted through the cannula, and artificial cerebrospinal fluid was pumped 
through at a rate of 2µl/min using a syringe pump (Harvard Apparatus, Cambridge, MA). Two 
hours post-insertion, sampling began and continued for 7 hours. Following the end of the 
sampling session, the probe was removed, and after euthanasia histological analyses were 
performed to verify placement sites. Samples were frozen and analyzed for DA content using 
reverse-phase HPLC with electrochemical detection (ESA, New Bedford, MA, USA; channel 1: 
−100 mV, channel 2: +200 mV, guard cell: +350 mV). Each liter of mobile phase contained 
27.6g sodium phosphate monobasic monohydrate, 8% methanol, 750 µL 0.1 M EDTA, and 2000 
µL 0.4 M sodium octyl sulfate (SOS) dissolved in dH2O (pH=4.5). Flow rate was 1.0 mL/min. 
DA standards were assayed before, during, and after the collection of dialysis samples.  
 
Experiments  
Experiment 1: Ability of the MAO-B inhibitor deprenyl to attenuate tetrabenazine-induced 
tremulous jaw movements  
A group of 8 rats was used to assess the ability of the MAO-B inhibitor deprenyl to 
attenuate tremulous jaw movements induced by the acute administration of TBZ (2.0 mg/kg). A 
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within-groups design was utilized for this study, with all rats receiving all drug treatments in a 
randomly varied order (one treatment per week; no treatment sequences repeated). On the test 
day, each rat received an IP injection of either 1.0 ml/kg vehicle solution (80% saline, 20% 
DMSO) or 2.0 mg/kg TBZ. Ninety minutes later, rats received an IP injection of either 1.0 ml/kg 
0.9% saline (vehicle), 7.5, or 15 mg/kg deprenyl. Twenty minutes after the second injection, rats 
were placed in the Plexiglas observation chamber and allowed to habituate for 10 minutes. TJMs 
were then counted for 15 minutes, with the observation period divided into three 5-min epochs. 
 
Experiment 2: Neurochemical analyses of extracellular DA in the VLS after administration of 
TBZ and deprenyl  
Rats were operated with dialysis guide cannulae, allowed to recover, and had dialysis 
probes inserted on the morning of the drug test. On test days, rats (n=18) were randomly 
assigned to one of three treatment conditions: Veh/Veh (n=5), TBZ/Veh (n=6), or TBZ/Dep 
(n=7). After collection of sample 6, rats received an IP injection of either 1.0 ml/kg vehicle 
solution (80% saline, 20% DMSO) or 2.0 mg/kg TBZ. Ninety minutes later, rats received an IP 
injection of either 1.0 ml/kg 0.9% saline (vehicle), or 15 mg/kg deprenyl.  
 
Data Analysis  
The data for experiment 1 was analyzed using a repeated measures analysis of variance 
(ANOVA). Average TJMs per five-minute observation period were calculated and used in the 
ANOVA calculations. A computerized statistical program (SPSS 21.0 for Windows) was used to 
perform these analyses. When there was a significant ANOVA, planned comparisons using the 
overall error term were used to assess the differences between each dose and the control 
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condition (the number of comparisons was restricted to the number of treatments minus one 
(Keppel, 1991). For experiment 2, an ANOVA was used to test for differences in baseline DA 
levels between the three conditions. Changes in DA levels were calculated as percentage change 
from baseline. Three repeated measures factorial ANOVAs were performed: Veh/Veh vs 
TBZ/Veh; TBZ/Veh vs TBZ/Dep; Veh/Veh vs TBZ/Dep. When there was a significant 
interaction, analysis of simple effects was used to compare differences between the two 
conditions at each 30 minute sample.  
 
4.3 Results  
Experiment 1: Ability of the MAO-B inhibitor deprenyl to attenuate tetrabenazine-induced 
tremulous jaw movements  
Repeated measures ANOVA revealed a significant overall effect of deprenyl treatment 
on TBZ-induced TJMs (F(3,21) = 12.496; p<0.0001). 2.0 mg/kg TBZ significantly induced 
TJMs compared to vehicle control (planned comparisons, p<0.05) and deprenyl (15.0 mg/kg) 
significantly reduced TBZ-induced TJMs (planned comparisons, p<0.05) (Figure 4.1).  
 
Experiment 2: The effect of TBZ and deprenyl administration on extracellular dopamine levels in 
the ventrolateral striatum  
ANOVA revealed no differences in baseline DA levels (nanograms) in the ventrolateral 
striatum across conditions. (F(2,17) = 1.064, p> 0.05; Veh/Veh: 0.025 + 0.007; TBZ/Veh: 0.026 
+ 0.006; TBZ/Dep: 0.044 + 0.013). Repeated measures factorial ANOVA revealed a significant 
effect of sample (F(6, 90) = 10.654; p<0.001), a significant treatment by sample interaction 
(F(12, 90) = 3.398; p<0.001), but no significant effect of treatment. To identify the source of the 
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interaction, individual repeated measures factorial ANOVAs comparing each of the treatment 
groups (Veh/Veh vs TBZ/Veh; TBZ/Veh vs TBZ/Dep; Veh/Veh vs Veh/Dep) were performed.  
Repeated measures factorial ANOVA revealed a significant effect of treatment (F(1, 9) = 
171.099l; p<0.001) and sample (F(6, 54) = 12.212; p<0.001) and a significant treatment by 
sample interaction (F(6, 54) = 8.772; p<0.001) between animals in the Veh/Veh vs. TBZ/Veh 
conditions. Analysis of simple effects revealed that administration of TBZ increased extracellular 
DA in sample 1 (F(1, 9) =7.63; p<0.05), and decreased extracellular DA in the VLS compared to 
the vehicle condition in samples 3 (F(1, 9) = 5.914; p<0.05), 4 (F(1, 9) =8.755; p<0.05), and 5 
(F(1, 9) = 7.273; p<0.05).   
Repeated measures factorial ANOVA revealed a significant effect of treatment (F(1, 11) 
= 111.149; p<0.001) and sample (F(6,66) = 12.428; p<0.001) and a significant treatment by 
sample interaction (F(6,66) = 2.433; p<0.05) between animals in the TBZ/Veh and TBZ/Dep 
conditions. Analysis of simple effects revealed that coadministration of TBZ plus deprenyl 
increased extracellular DA in the VLS compared to TBZ alone in sample 5 (F(1, 11) = 5.400; 
p<0.05). Repeated measures factorial ANOVA revealed a significant effect of treatment (F(1, 
10) = 97.428; p<0.001) sample (F(6, 60) = 2.556; p<0.05) but no treatment by sample interaction 
between animals in the Veh/Veh and TBZ/Dep conditions. 
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Figure 4.1: Effect of MAO-B inhibition on tetrabenazine (2.0 mg/kg) induced TJMs. Mean (+ 
SEM) number of jaw movements (per 5 min) in rats treated with vehicle (Veh/Veh), 
tetrabenazine plus vehicle (TBZ/Veh), and tetrabenazine plus various doses (7.5, 15.0 mg/kg) of 
deprenyl.  #significant difference from Veh/Veh (p<.05); *significant difference from TBZ/Veh 
(p<0.05) 
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Figure 4.2: Effect of tetrabenazine and deprenyl on extracellular DA in VLS. Mean (+ SEM) 
extracellular DA (expressed as percent baseline) in 30-minute samples. A baseline sample was 
collected prior to injection, followed by seven post-drug samples. #significant difference from 
Veh/Veh (p<0.05); *significant difference from TBZ/Veh (p<0.05) 
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Chapter 5: Fluoxetine administration exacerbates oral tremor and striatal dopamine 
depletion in a rodent pharmacological model of Parkinsonism  
Published; Podurgiel et al., 2015  
5.1 Introduction 
Idiopathic Parkinson’s Disease (PD) is caused by a progressive degeneration of the 
dopamine (DA) producing neurons of the substantia nigra pars compacta. In addition to 
idiopathic PD, there also are drug-induced forms of Parkinsonism, which are caused by 
administration of drugs that block DA receptors or deplete DA. Parkinsonism is a family of 
motor disorders that is characterized by several cardinal motor symptoms, including resting 
tremor, akinesia, bradykinesia, and rigidity (Marsden et al., 1975; Ostrem and Galifianakis, 
2010). These motor abnormalities can be modeled in rodents using various behavioral 
paradigms. Locomotor activity can be examined as an indicator of akinesia/bradykinesia, and the 
tremulous jaw movement (TJM) model can be used to evaluate resting tremor. TJMs are defined 
as rapid vertical deflections of the lower jaw that resemble chewing but are not directed at any 
particular stimulus (Salamone et al., 1998) and are generated by conditions that parallel those 
that induce Parkinsonism in humans, including neurotoxic or pharmacological dopamine (DA) 
depletion, DA antagonism, and cholinomimetic administration (Jicha and Salamone, 1991; 
Salamone et al., 2008; Betz et al., 2009; Collins et al., 2011; Podurgiel et al., 2013a). TJMs occur 
in the frequency range characteristic of Parkinsonian resting tremor (3-7.5 Hz; Salamone et al., 
1998; Cousins et al., 1998; Collins et al., 2011; Podurgiel et al., 2013a) and can be attenuated by 
administration of antiparkinsonian agents, including L-DOPA (Cousins et al., 1997), DA 
agonists (Cousins et al., 1997; Salamone et al., 2005), muscarinic antagonists (Cousins et al., 
1997; Betz et al., 2009) and adenosine A2A antagonists (Correa et al., 2004; Simola et al., 2004; 
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Tronci et al., 2007; Salamone et al., 2008; Betz et al., 2009; Collins et al., 2011, 2012; Podurgiel 
et al., 2013a).  
While Parkinsonism is primarily characterized by the generation of the cardinal motor 
symptoms, patients with PD also suffer from a variety of significant non-motor symptoms, 
including autonomic dysfunction, sensory abnormalities, gastrointestinal issues, sleep disorders, 
and	  neuropsychiatric disturbances (Ostrem and Galifianakis, 2010; Barone, 2011). 
Neuropsychiatric symptoms are common even in the earliest stages of the disease, and can 
considerably affect the daily functioning and overall quality of life of PD patients (Aarsland et 
al., 2009; Barone, 2011). Depression, in particular, has been identified as the most significant 
predictor of health-related quality of life in PD (Schrag et al, 2000; Chen and Marsh, 2013), and 
systematic review and analysis suggest that 35-40% of patients with PD also experience 
clinically significant symptoms of depression (Slaughter et al., 2001; Aarsland et al., 2009).  
Selective serotonin reuptake inhibitors (SSRIs) are prescribed more often than any other 
class of antidepressants for PD patients (Veazey et al., 2005; Aarsland et a.l, 2009; Chen and 
Marsh, 2013). Yet controlled clinical trials, meta-analyses, and systematic review collectively 
suggest that SSRIs are no more effective than placebo in treating depression in the context of PD 
(Skapinakis et al., 2010; Aarsland et al., 2009). Furthermore, SSRI administration has been 
associated with a number of motor side-effects, and may be implicated in increased motor 
disability in PD patients (Leo, 1996; Richard et al., 1997; Govoni et al., 2001; Veazey et al., 
2005; Aarsland et al., 2009). There are presently more than 100 published reports of 
“extrapyramidal” symptoms (e.g. dystonia, akathisia, dyskinesia, and Parkinsonism, including 
tremor) associated with SSRI treatment; fluoxetine (Prozac; FLX) has been implicated in the 
majority of these reports (Madhusoodanan et al., 2010).  
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FLX primarily functions as an inhibitor of the serotonin (5-HT) transporter, preventing 
uptake of 5-HT and ultimately resulting in increased activation of a variety of 5-HT receptors, 
including the 5-HT1A, 5-HT2A, and 5-HT2C receptors found throughout the striatum (Nutt et al., 
1999; Alex and Pehek, 2007; More et al., 2014). Interactions between 5-HT and DA 
neurotransmission are strongly implicated in the generation of motor dysfunctions associated 
with FLX treatment (Morelli et al., 2011), as DA release and metabolite production are inhibited 
by increased synaptic levels of 5-HT (Govoni et al., 2001; Morelli et al., 2011). Activation of 5-
HT2C receptors has been linked to decreased DA synthesis, neural activity and release in the 
nigrostriatal and mesolimbic DA pathways (Alex and Pehek, 2007; More et al., 2014). In rodent 
models, FLX administration has been shown to potentiate haloperidol-induced catalepsy and 
bradykinesia in a dose-dependent manner (Tatara et al., 2012; More et al., 2014).  
Thus, FLX treatment may result in increased motor deficits in PD patients due to 5-HT-
mediated exacerbation of DA depletion and basal ganglia dysfunction. The present study sought 
to characterize this interaction using a pharmacological rodent model of Parkinsonism. 
Tetrabenazine (TBZ) is a reversible and selective inhibitor of the type-2 vesicular monoamine 
transporter (VMAT-2) that is used to treat chorea associated with Huntington’s disease. 
Huntington’s disease patients taking TBZ can experience adverse events, including Parkinsonian 
motor symptoms and depression (Kenney et al., 2007; Frank, 2009).  Recent studies show that 
high doses of TBZ in rodents (e.g., 2.0 mg/kg in rats, 5.0-10.0 mg/kg in CD1 mice) can induce 
TJMs and suppress locomotor activity (Podurgiel et al., 2013a). In the present studies, 
Experiment 1 examined the effect of acute administration of FLX (2.5, 5.0, or 10.0 mg/kg) on 
TJMs and locomotor suppression induced by a low dose of TBZ (0.75 mg/kg) in rats; this low 
dose was selected because it is used to study rat models of the motivational symptoms of 
51 	  
depression (Nunes et al., 2013; Randall et al., 2014). To test the hypothesis that 5-HT2 family 
receptors are involved in the neural mechanisms underlying this behavior, experiment 2 assessed 
the ability of the 5-HT2A/2C antagonist mianserin to attenuate TJMs induced by co-administration 
of TBZ (0.75 mg/kg) and FLX (5.0 mg/kg). Experiment 3 examined tissue levels of DA in the rat 
ventrolateral neostriatum (VLS), which is the homologue of the ventral putamen and the striatal 
subregion most closely associated with the production of TJMs (Jicha and Salamone, 1991; 
Salamone et al., 1998, 2008; Simola et al., 2004, Betz et al., 2009), after administration of TBZ 
(0.75 mg/kg), FLX (5.0 mg/kg), and mianserin (5.0 mg/kg).  
 
5.2 Materials and Methods 
Animals  
 Adult male Sprague Dawley rats (N=34) weighing 350-450g during the course of the 
experiment had ad libitum access to lab chow and water (Harlan Laboratories, Indianapolis, IN). 
They were pair-housed in a colony that was maintained at approximately 23°C and had a 12-hour 
light/dark cycle (lights on at 0700 hrs). These studies were conducted according to University of 
Connecticut and NIH guidelines for animal care and use.   
 
Drug Treatment Procedures and Dose Selection 
 Tetrabenazine (9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7, 11b 
hexahydrobenzo[a]quinolizin-2-one; TBZ), the VMAT-2 inhibitor, was purchased from Tocris 
Bioscience (Bristol, UK). TBZ was dissolved in a vehicle solution of 0.9% saline (80%) and 
dimethylsulfoxide (DMSO) (20%). Ten µl hydrochloric acid (HCl)/mL volume was then added 
to get the drug completely into solution. Fluoxetine ((±)-N-Methyl-γ-[4- 
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(trifluoromethyl)phenoxy]benzenepropanamine hydrochloride; FLX) was purchased from 
Sigma-Aldrich Corporation (Saint Louis, MO, USA). FLX was dissolved in 0.9% saline. 
Mianserin hydrochloride (1,2,3,4,10,14b-Hexahydro-2-methyldibenzo[c,f]pyrazino[1,2-
a]azepine hydrochloride) was purchased from Tocris Bioscience (Bristol, UK). Mianserin was 
dissolved in 0.3% tartaric acid. A dose of 0.75 mg/kg TBZ was selected based on previous 
studies with animal models of the motivational symptoms of depression (Nunes et al, 2013; 
Randall et al, 2014), and also on studies showing that this dose was lower than those that 
produce substantial TJMs (Podurgiel et al., 2013), and was low enough to have a preferential 
effect on DA levels (Tanra et al. 1995). The doses of FLX used in experiment 1 (2.5, 5.0, and 
10.0 mg/kg) were selected based on extensive pilot work involving animal models of the 
motivational symptoms of depression (Yohn et al, unpublished data). Doses of FLX for 
experiment 2 were based on results from experiment 1. Doses of mianserin (2.5 and 5.0 mg/kg) 
were selected based on previous work conducted in our laboratory (Carlson et al, 2003).  
 
Behavioral Procedures 
Tremulous Jaw Movements. Observations of rats took place in a 30 × 30 × 30 cm clear 
Plexiglas chamber with a wire mesh floor, which was elevated 42 cm from the table top. This 
allowed for the viewing of the animal from several angles, including underneath. TJMs were 
defined as rapid vertical deflections of the lower jaw that resembled chewing but were not 
directed at any particular stimulus (Salamone et al., 1998). Each individual deflection of the jaw 
was recorded using a mechanical hand counter by a trained observer, who was blind to the 
experimental condition of the rat being observed. Separate studies with two observers 
demonstrated an inter-rater reliability of r = 0.999 (p < 0.01) using these methods. 
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Locomotor Activity. Locomotor activity was assessed by placing the rat in an automated 
activity chamber (28 × 28 × 28 cm) enclosed in a sound-attenuating shell. The floor of the 
chamber was elevated 6 cm above the chamber bottom and was composed of two moveable 
wire-mesh panels (25 × 12 cm) that were further divided into four quadrants by means of a 
central metal rod. As the rat entered each quadrant, a slight vertical movement of the mesh 
panels closed a microswitch located outside of the locomotion chamber. Each switch closure was 
detected and recorded by a computer program, written in MedPC (Med Associates, Inc., Georgia, 
VT, USA), as a single activity count. The locomotor activity session was 18-min in length. These 
methods of measuring locomotion have been used previously to assess the effects of DA 
antagonists and TBZ on locomotion (Salamone et al., 2008; Podurgiel et al., 2013a). 
 
Tissue Collection and HPLC 
 Rats were exposed to carbon dioxide for 30 s and decapitated. Brains were quickly 
removed and frozen on a Leitz Wetzlar microtome. Coronal sections 750 µm thick were cut 
through the ventrolateral neostriatum (VLS). A 16-gauge stainless steel tube was used to dissect 
bilateral cylindrical samples from the VLS. The VLS was selected because of a substantial 
literature showing that this site is the most critical striatal subregion involved in the regulation of 
TJMs.  Several papers have included placement controls, including injections into multiple 
striatal sites, multiple drugs or lesion methods, and injections into control sites dorsal to the VLS 
(Kelley et al., 1989; Salamone et al., 1990; Jicha and Salamone 1991; Cousins et al., 1998; 
Simola et al., 2004).  Since previous work has shown that DA depletions could induce TJMs 
when 6-OHDA was injected into the VLS, but not other striatal sites (Jicha and Salamone, 1991), 
it was decided that the VLS was the critical neostriatal locus upon which to focus for studies 
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involving DA tissue levels.  These tissue samples were then placed in 200 µL of 0.1 N perchloric 
acid, and then homogenized, centrifuged and frozen. The supernatant was subsequently analyzed 
using high-performance liquid chromatography with electrochemical detection (HPLC-EC; ESA 
Coulochem II system). The electrochemical parameters were as follows: channel 1= -100 mV, 
channel 2 = +200mV, guard cell = +350 mV. Each liter of mobile phase contained 27.6 g sodium 
phosphate monobasic, 8.0% methanol, 750 µl of 0.1 M EDTA, and 2875 µl of 0.4 M sodium 
octyl sulfate dissolved in deionized ultrapure H2O with a final pH of 4.5. The flow rate was 1.0 
ml/min. 
 
Experiments  
Experiment 1: Ability of FLX to exacerbate TBZ-induced TJMs tremulous jaw movements and 
locomotor suppression 
 A group of 12 rats was used to assess the effects of the acute administration of FLX on 
the motor symptoms induced by 0.75 mg/kg TBZ. A within-groups design was utilized for this 
study, with all rats receiving all drug treatments in a randomly varied order (one treatment per 3 
week block; no treatment sequences repeated). On the test day, which occurred once every 3 
weeks, each rat received an IP injection of either 1.0 ml/kg vehicle solution (80% saline, 20% 
DMSO) or 0.75 mg/kg TBZ. Thirty min later, rats received an IP injection of either 1.0 ml/kg 
0.9% saline (vehicle) or 2.5, 5.0, or 10.0 mg/kg FLX. Thus, there were six conditions being 
studied (vehicle/vehicle, TBZ/vehicle, vehicle/10.0 mg/kg FLX, and TBZ with either 2.5, 5.0 or 
10.0 mg/kg FLX). One hour and twenty min after the second injection, rats were placed in the 
Plexiglas observation chamber and allowed to habituate for 10 min. TJMs were then counted for 
15 minutes, with the observation period divided into three 5-min epochs. Upon completion of the 
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TJM assessment, locomotor activity was assessed in the same group of 12 rats in an 18-min 
session using the procedure outlined above.  
 
Experiment 2: Ability of mianserin to attenuate TJMs induced by co-administration of TBZ and 
FLX  
 A group of 8 rats was used to assess the ability of the 5-HT2A/2C antagonist mianserin to 
attenuate TJMs induced by the acute co-administration of TBZ (0.75 mg/kg) and FLX (5.0 
mg/kg). A within-groups design was used, with all rats receiving all drug treatments in a 
randomly varied order (one treatment per 3 week block; no treatment sequences repeated). On 
the test day, which occurred once every 3 weeks, each rat received an IP injection of either 1.0 
ml/kg vehicle solution (80% saline, 20% DMSO) or 0.75 mg/kg TBZ. Thirty minutes later, rats 
received an IP injection of either 1.0 ml/kg 0.9% saline (vehicle) or 2.5, 5.0, or 10.0 mg/kg FLX. 
Fifty min later, rats received a subcutaneous injection of either 1.0 ml/kg 0.3% tartaric acid 
(vehicle) or 2.5 or 5.0 mg/kg mianserin. Thirty min after the third injection, rats were placed in 
the Plexiglas observation chamber and allowed to habituate for 10 min. TJMs were then counted 
for 15 min, with the observation period divided into three 5-min epochs. 
 
Experiment 3: Neurochemical analyses for tissue DA after administration of TBZ, FLX, and 
mianserin  
 A total of 34 rats were used to examine tissue levels of DA after administration of TBZ, 
FLX, and mianserin (the 12 rats from experiment 1, the 8 rats from experiment 2, and 14 
additional rats that received drug treatments matching those of the animals used for the first two 
experiments; these additional animals were needed because the tissue assay experiments required 
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a larger total N due to the between-groups design).  A between-groups design was utilized for 
this study, with rats being randomly assigned to one of four treatment conditions: Veh/Veh/Veh 
(n=9), TBZ/Veh/Veh (n=9), TBZ/FLX/Veh (n=8), or TBZ/FLX/Mianserin (n=8). Rats received 
an IP injection of either 1.0 ml/kg vehicle solution (80% saline, 20% DMSO) or 0.75 mg/kg 
TBZ. Thirty min later, rats received an IP injection of either 1.0 ml/kg 0.9% saline (vehicle) or 
5.0 mg/kg FLX. Fifty min later, rats received a subcutaneous injection of either 1.0 ml/kg 0.3% 
tartaric acid (vehicle) or 5.0 mg/kg mianserin. Forty min later, tissue collection was performed. 
One week later, samples were analyzed for DA content using HPLC-EC as described above.  
 
Data Analysis 
 The data for experiments 1 and 2 were analyzed using a repeated measures analysis of 
variance (ANOVA). Average TJMs per five-minute observation period were calculated and used 
in the ANOVA calculations. A computerized statistical program (SPSS 21.0 for Windows) was 
used to perform these analyses. When there was a significant ANOVA, planned comparisons 
using the overall error term were used to assess the differences between each dose and the 
control condition (Keppel, 1991; the number of comparisons was restricted to the number of 
treatments minus one (Keppel, 1991). For experiment 3, DA levels were expressed as 
nanogram/mg wet weight of tissue. Data was analyzed using a between groups analysis of 
variance (ANOVA). When there was a significant ANOVA, planned comparisons using the error 
term from the paired conditions were used to assess the differences between conditions. 
 
 
 
57 	  
5.3 Results  
Experiment 1: Ability of FLX to exacerbate TBZ-induced TJMs and locomotor suppression  
Repeated measures ANOVA revealed a significant overall treatment effect on TJMs 
(Figure 5.1; F(5,55) = 19.307; p<0.05). The 0.75 mg/kg dose of TBZ significantly induced TJMs 
compared to vehicle controls (planned comparisons, p<0.05). Co-administration of TBZ (0.75 
mg/kg) with 2.5, 5.0, or 10.0 mg/kg doses of FLX significantly increased TJMs from TBZ alone 
(planned comparisons, p<0.05). Repeated measures ANOVA also revealed a significant overall 
treatment effect for locomotion (Figure 5.2; F(5,55) = 6.757; p<0.05). The 10.0 mg/kg dose of 
FLX significantly suppressed locomotor activity as compared to vehicle controls (planned 
comparisons, p<0.05). Co-administration of 0.75 mg/kg TBZ and 2.5, 5.0, or 10.0 mg/kg doses 
of FLX significantly reduced locomotor activity compared to TBZ alone (planned comparisons, 
p<0.05).  
 
Experiment 2: Ability of mianserin to attenuate TJMs induced by coadministration of TBZ and 
FLX  
 Repeated measures ANOVA revealed a significant overall treatment effect on TJMs 
(Figure 5.3; F(4,28) = 3.451; p<0.05). Co-administration of 0.75 mg/kg TBZ and 5.0 mg/kg FLX 
significantly increased TJMs from the vehicle condition (planned comparisons, p<0.05) and TBZ 
alone (planned comparisons, p<0.05). Both doses of mianserin (2.5, 5.0 mg/kg) significantly 
reduced TJMs induced by co-administration of TBZ (0.75 mg/kg) and FLX (5.0 mg/kg) (planned 
comparisons, p<0.05).  
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Experiment 3: Neurochemical analyses for tissue DA levels after administration of TBZ, FLX, 
and mianserin 
 Between subjects ANOVA revealed a significant overall treatment effect on DA levels in 
the VLS (Figure 5.4; F(3,30) = 21.489; p<0.0001). Administration of TBZ (0.75 mg/kg) 
decreased DA levels in the VLS compared to the vehicle condition (F(1,16) = 4.49; p<0.05). Co-
administration of TBZ (0.75 mg/kg) and FLX (5.0 mg/kg) further decreased DA levels in the 
VLS compared to TBZ alone (F(1,15) = 4.54; p<0.05). Co-administration of mianserin (5.0 
mg/kg) with TBZ (0.75 mg/kg) and FLX (5.0 mg/kg) increased DA levels compared to TBZ and 
FLX alone (F(1,14) = 4.60; p<0.05).  
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Figure 5.1: Mean (+ SEM) number of TJMs per 5 min observation period in rats that received 
injections of vehicle (Veh/Veh), 0.75 mg/kg tetrabenazine (TBZ/Veh), or various mg/kg doses of 
fluoxetine (FLX; 2.5-10.0 mg/kg) in combination with TBZ.   
# different from Veh/Veh, p < 0.05; * TBZ/FLX different from TBZ/Veh, p < 0.05 
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Figure 5.2: Mean (+ SEM) number of locomotor activity counts in rats that received injections 
of vehicle (Veh/Veh), 0.75 mg/kg tetrabenazine (TBZ/Veh), or various mg/kg doses of 
fluoxetine (FLX; 2.5-10.0 mg/kg) in combination with TBZ.   
# different from Veh/Veh, p < 0.05; * TBZ/FLX different from TBZ/Veh, p < 0.05 
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Figure 5.3: Mean (+ SEM) number of TJMs per 5 min observation period in rats that received 
injections of vehicle (Veh/Veh), 0.75 mg/kg tetrabenazine (TBZ/Veh), 5.0 mg/kg fluoxetine 
(FLX), and various doses of mianserin (Mia; 2.5-5.0 mg/kg) in combination with TBZ and FLX.   
# different from Veh/Veh, p < 0.05; + TBZ/FLX/Veh different from TBZ/Veh/Veh, p < 0.05;  
* TBZ/FLX/Mia different from TBZ/FLX/Veh, p < 0.05 
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Figure 5.4: Mean (+ SEM) amount of DA in ventrolateral neostriatum (ng/mg tissue) in rats that 
received injections of vehicle (Veh/Veh), 0.75 mg/kg tetrabenazine (TBZ/Veh), 5.0 mg/kg 
fluoxetine (FLX), and 5.0 mg/kg mianserin (Mia) in combination with TBZ and FLX.   
# different from Veh/Veh, p < 0.05; + TBZ/FLX/Veh different from TBZ/Veh/Veh, p < 0.05;  
* TBZ/FLX/Mia different from TBZ/FLX/Veh, p < 0.05 
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Chapter 6: Tremor-related subthalamic and cortical local field potentials associated with 
pilocarpine-induced oral tremor 
6.1 Introduction  
Parkinsonism is a broad family of disorders that includes idiopathic Parkinson’s disease 
(PD), which results from degeneration of nigrostriatal dopamine (DA) neurons (Hornykiewicz, 
1973), as well as drug-induced Parkinsonism (DIP). DIP is induced by drugs that interfere with 
DA transmission (e.g. DA antagonists, DA depleting agents; Marsden et al., 1975; McEvoy, 
1983), and cholinomimetics such as anticholinesterases and muscarinic agonists (Ott and 
Lannon, 1992; Aarsland et al., 2003). The cardinal motor symptoms of Parkinsonism include 
akinesia, bradykinesia, rigidity, and resting tremor, which typically occurs in the 3-7 Hz 
frequency range (Marsden et al., 1975). DIP is produced in rodents by the same pharmacological 
agents that induce human Parkinsonism, and resting tremor can be modeled in rodents using the 
tremulous jaw movement (TJM) model. TJMs, defined as “rapid, repetitive vertical deflections 
of the lower jaw that resemble chewing but are not directed at any particular stimulus” 
(Salamone et al., 1998), have a local frequency of 3-7 Hz, which parallels that of Parkinsonian 
resting tremor (Salamone et al., 1998; Cousins et al., 1998; Collins et al., 2010; Podurgiel et al., 
2013a). TJMs are induced by neurotoxic or pharmacological depletion of DA, DA antagonism, 
and cholinomimetic drugs (Jicha and Salamone 1991; Salamone et al., 1998; Podurgiel et al., 
2013b, 2015), and can be attenuated by co-administration of antiparkinsonian agents such as L-
DOPA, DA agonists, muscarinic antagonists, MAO inhibitors, and adenosine A2A antagonists 
(Cousins et al., 1997; Simola et al., 2004, 2006; Salamone et al., 2005, 2008a,b; Podurgiel et al., 
2013a,b). Considerable evidence indicates that TJMs in rodents are a valid model for the 
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exploration of the pharmacology, neurochemistry and physiology of drug-induced tremor 
(Salamone et al., 1998, 2008b, 2013; Collins-Praino et al., 2011; Podurgiel et al., 2013a,b, 2015). 
 Exaggerated neuronal synchrony has been recorded in basal ganglia and cortex of PD 
patients, with the beta band (~15-30 Hz) being the best-characterized oscillation (Brown 2003; 
Hammond et al., 2007; Oswal et al., 2013). Increased beta activity has been observed in the 
cortex (George et al., 2013) and subthalamic nucleus (STN) of PD patients, and it has been 
suggested that excessive synchrony in this frequency range contributes to motor dysfunction 
(Levy et al., 2002; Brown and Williams, 2005; Kuhn et al., 2006). Reduction in STN beta 
activity correlates with improvement in akinesia and rigidity in PD patients (Levy et al., 2002; 
Kuhn et al., 2006). While the literature supports a link between increased cortical and basal 
ganglia beta power and the development of akinesia/rigidity, beta activity generally does not 
correlate with the severity of resting tremor (Kuhn et al., 2005; Hammond et al., 2007; Oswal et 
al., 2013). Rather, the development of tremor in PD patients has been shown to be associated 
with the emergence of oscillations in the tremor frequency range (3-7 Hz) in the cortex and basal 
ganglia (Timmerman et al., 2003; Reck et al., 2009; Hirschmann et al., 2013; Oswal et al., 2013). 
Timmerman et al. (2003) reported strong coherence between electromyograph (EMG) activity of 
forearm muscles and activity in the contralateral primary motor cortex (M1), at tremor (3-7 Hz) 
and double tremor frequency (7-13 Hz) in PD patients off medication. Similar patterns of activity 
have been observed in the STN of PD patients, as indicated by power spectra peaks at tremor 
frequency and tremor harmonics, as well as significant coherence between STN local field 
potentials (LFPs) and EMG activity at tremor frequency (Brown et al., 2001; Levy et al., 2000; 
Liu et al., 2002; Wang et al., 2005; Reck et al., 2009).  
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These clinical reports support the idea that cortical and STN power and coherence at 
tremor frequencies increase with the manifestation of tremor, but this phenomenon has not been 
modeled in rodents. Therefore, the present study characterized the temporal pattern of oral EMG 
activity and associated changes in LFPs recorded from M1 and STN during the TJMs induced by 
the muscarinic agonist pilocarpine (Collins et al., 2010; Collins-Praino et al., 2012; Salamone et 
al., 2013). 
 
6.2 Materials and Methods  
Animals 
A total of 5 adult male Sprague Dawley rats (Harlan Sprague Dawley, Indianapolis, IN) 
with no prior drug experience were used in the present experiment. The rats weighed 350-450 g 
during the course of the experiment and had ad libitum access to lab chow and water. Animals 
were group-housed prior to surgery in a colony that was maintained at approximately 23°C and 
had a 12-hour light/dark cycle (lights on at 0700 hrs).  Post-surgery, animals were single housed 
to avoid over grooming around the surgical implant. This study was conducted according to 
University of Connecticut and NIH guidelines for animal care and use. 
 
Drug Treatment Procedures and Dose Selection 
Pilocarpine was purchased from Sigma Aldrich Chemical (St. Louis, MO) and dissolved 
in 0.9% saline. The dose of pilocarpine (4.0 mg/kg) was based on previous experiments showing 
significant induction of jaw movements at this dose (see Collins et al. 2010a for further details). 
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Surgical Procedures  
Rats were anesthetized with a 1.0 ml/kg IP injection of a cocktail solution containing 10.0 
ml of 100 mg/mL ketamine plus 0.75 ml of 20.0 mg/ml xylazine (Phoenix Scientific, Inc., St. 
Joseph, MO, USA). Rats were placed in a stereotaxic frame (Kopf, Tujunga, CA, USA), and a 
midline scalp incision was made. Two electrode arrays consisting of 50 µm tungsten wire 
(California Fine Wire Company, Grover Beach, CA) were bilaterally implanted with a 27-gauge 
needle approximately 5.0 mm deep into the lateral temporalis muscle (4 EMG electrodes per 
animal). Previous research has demonstrated that the lateral temporalis muscle is the jaw muscle 
that shows activity most closely related to TJMs (Cousins et al., 1998). Burr holes were drilled 
through the skull over the STN (R hemisphere) and M1 (L hemisphere), and two –four electrode 
arrays were implanted (8 LFP electrodes per animal). LFP electrode arrays were comprised of 
four linearly spaced 50 µm tungsten wires (California Fine Wire Company, Grover Beach, CA). 
Electrode wire was arranged and separated by fused silica tubing (Polymicro Tubing, Phoenix, 
AZ), attached to female pins (Omnetics, Minneapolis, MN) and secured in a rectangular five by 
four pin array.  Two stainless steel watch screws driven into the skull above the cerebellum 
served as indifferent and ground electrodes. Supplementary anchor screws were positioned as 
necessary and the entire head-stage ensemble was fortified with dental acrylic. The surgical 
coordinates, for which bregma and the top of the skull was used as the reference point, were as 
follows: STN (AP: -3.6, ML: +/- 2.5, DV: -7.5); M1 (AP +1.0, ML +1.9, DV -2.5). Rats 
recovered for one week post-surgical procedure. 
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Behavioral Measures  
 
Following a one-week recovery period, rats were given an acute IP injection of saline 
(vehicle). Immediately after vehicle injection, rats were placed into a Plexiglas observation 
chamber and allowed to habituate for 10 min. At the beginning of this habituation period, the 
animals were connected to the recording apparatus by a multi-channel tether (Neuralynx, 
Bozeman, MT) that was attached to a pulley system in the ceiling. Following the habituation 
period, a trained observer counted tremulous jaw movements for fifteen minutes. TJMs were 
defined as rapid vertical deflections of the lower jaw that resembled chewing but were not 
directed at any particular stimulus (Salamone et al. 1998). At the end of the 15-minute 
observation period, rats were disconnected and returned to their home cages. This procedure was 
repeated with administration of 4.0 mg/kg pilocarpine 24 hours later.  
 
Electrophysiological Data Acquisition and Analysis 
Following the habituation period, wide-band electrical activity was recorded (5050.5 
samples/sec) for 15 minutes using a Neuralynx data acquisition system (Bozeman, MT). TJMs 
were counted simultaneously by a trained observer and noted using event markers through 
Cheetah data acquisition software (version 5.6.3; Neuralynx, Bozeman, MT).  Following data 
acquisition and during subsequent offline analysis, data were imported into Matlab R2014a 
(Mathworks, Natick, MA). The raw EMG signal was bandpass filtered between 500 and 1500 Hz 
and the Hilbert transform was computed on the bandpass filtered signal.  In this regard, the 
instantaneous (5050.5 samples/sec) EMG envelope amplitude (magnitude of Hilbert transform) 
was obtained over time. The EMG signal was then full wave rectified and all raw EMG traces 
presented in the current analysis represent this full wave rectified signal.  Event markers were 
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simultaneously imported into Matlab and plotted along with the EMG signal.  The presence or 
absence of these event markers was used to identify TJM and no TJM epochs, respectively. Raw 
LFP data were imported into Matlab R2014a and down-sampled by a factor of 10 during offline 
analysis, thus changing the sampling rate to 505.05 samples/s (Hz; 5050.5/10 = 505.05).  The 
raw LFP signal was lowpass filtered to remove high frequency chewing, chattering and/or teeth 
grinding artifacts (Fc = 200 Hz).  Then, the LFP signal was bandpass filtered for tremor (3-7 Hz) 
and beta frequency (15-30 Hz) and the Hilbert transform was computed on the bandpass filtered 
signals.  Data were examined during: 1) TJM epochs and, 2) No TJM epochs. 
All data analysis was conducted using custom written programs in MatLab R2014a 
(Mathworks, Natick, MA).  Power spectral density estimates were obtained using Welch’s 
averaged modified periodogram method (Welch, 1967) during epochs of TJMs and no TJMs. To 
extract the amplitude modulation (AM) frequency of the EMG signal (e.g., “tremor frequency”; 
3-7 Hz), power spectral density estimates were obtained from the envelope (magnitude of Hilbert 
transform) of the bandpass filtered EMG signal.  For LFP data, the power for tremor (3-7 Hz) 
and beta frequency (15-30 Hz) was calculated from the bandpass filtered signals and represented 
in units of mV2.  Average power was calculated by taking the sum of the power values within a 
given frequency range of interest (e.g, 3-7 Hz) and multiplying the sum by the spectral window 
resolution.  Centroid frequency or the weighted mean was calculated by first isolating the 
frequency range of interest (e.g., 3-7 Hz), indexing the power values within that frequency range 
and multiplying them.  Then, we divided those values by the sum of the previously indexed 
power values.  Lastly, we took the sum of the aforementioned. 
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Statistics 
 For each of the 5 animals a representative 2.2 second TJM was identified by a trained 
observer using event markers.  The TJM length was determined by the lowest responding animal.  
Further, within the same recording for each animal a subsequent 2.2 second no TJM time point 
was isolated as indicated by lack of event markers.  For each electrode, the average power and 
centroid frequency was computed within the frequency range of interest (3-7 Hz and 15-30 Hz) 
for TJM and no TJM epochs all the while discretized by electrode location (M1 and STN).  
Paired samples t-tests were computed to asses if there were significant differences in 1) average 
tremor power during TJMs and no TJMs for M1, 2) average tremor power during TJMs and no 
TJMs for STN, 3) average beta power during TJMs and no TJMs for M1, 4) average beta power 
during TJMs and no TJMs for STN, and 5) the same as 1-4, but for centroid frequency.  Further, 
we computed paired-samples t-tests to examine if there were differences in the aforementioned 
indices as a function of brain area (M1 and STN).  Lastly, paired samples t-tests were used to 
confirm significant differences in number of TJMs per 15 minute recording period across vehicle 
and pilocarpine recordings.  
 
Histology 
At the completion of the experiment, animals were deeply anesthetized with CO2 and 
perfused with 0.9% physiological saline followed by 3.7% formaldehyde solution.   The brains 
were extracted and stored in the formaldehyde solution for 1 week.   Then, brains were sliced (50 
µm sections) using a vibratome (Leica, Germany), mounted, Nissl stained using Cresyl Violet 
and cover-slipped allowing for verification of electrode placements.  Photomicrographs of 
electrode tracks were taken using a Nikon microscope connected to a Spot RT camera system, 
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digitized and prepared for presentation using Adobe Photoshop.  Consistent with the histological 
criteria employed by Brown et al. (2011) only placements that were within 500 µm of the STN, 
but dorsal to the cerebral peduncles and internal capsule were used for statistical analyses.    
 
6.3 Results   
Histological verification of electrode placements 
A total of 37 LFP electrodes (n= 19 M1 electrodes; n=19 STN electrodes) and 5 EMG 
electrodes across 5 animals were used in the current analysis. All animals contributed 1 EMG 
electrode, 3-4 M1 (Figure 6.1A) and 3-4 STN (Figure 6.1B) electrodes.  All EMG and LFP data 
were simultaneously recorded from each animal.  M1 electrodes terminated in all cortical layers 
but were more likely to terminate in deeper layers. Further, most STN electrodes were hits, 
although a few terminated slightly dorsally or anteriorly (data not shown), but still within the 500 
µm criteria put forth by Brown et al. (2011). 
 
Pilocarpine induces TJMs in the tremor frequency range (3-7 Hz) as reflected by EMG 
 Administration of pilocarpine significantly induced TJMs compared to vehicle control 
(Pilo mean: 603.6 + 314.4; Veh mean: 14.4 + 9.8; t(4) = 4.3, p <. 05).  Although vehicle 
conditions were used to verify the ability of pilocarpine to produce TJMs, large behavioral 
differences existed between vehicle and pilocarpine recordings that made electrophysiological 
comparisons between these two signals unsuitable (i.e., no tremor bursts, but more movement 
artifact, under vehicle conditions). Because of these differences, all EMG and LFP data analysis 
were conducted on epochs of TJMs and no TJMs within the pilocarpine recording for each 
animal.    
71 	  
  During bouts of jaw movement activity, the bandpass filtered (500-1500 Hz) and full 
wave rectified EMG signal was marked by rhythmic activity in the 3-7 Hz range (Figure 6.2A 
top, left; red).  Conversely, during periods of quiescence, no rhythmic activity was observed in 
the EMG (Figure 6.2A bottom, left; blue). Spectrograms indicated the same pattern of activity as 
the filtered EMG traces (Figure 6.2A, right). For the traces presented in Figure 6.2A, power 
spectral analysis revealed strong rhythmicity in the envelope of the EMG signal with a 
fundamental frequency of 4 Hz along with robust 2nd and 3rd harmonics (Figure 6.2B, red). 
Epochs of quiescence failed to exhibit amplitude modulation of the EMG signal within the 
tremor frequency range (Figure 6.2B, blue) and, show relatively little power overall.  Upon 
examination of the entire pilocarpine recording for the same representative animal, rodents 
continued to exhibit dominant power of the EMG envelope within the tremor frequency range, 
although the harmonics were largely attenuated (Figure 6.2C).  Importantly, this animal 
exhibited TJMs for 23.15% (3.47/15 minutes) of the recording session (Figure 6.2C right) 
indicating the robustness of the observed phenomenon. 
 
Power in the tremor frequency band increases during TJMs in M1 and STN 
 Upon examination of simultaneously recorded M1 LFPs for the same animal as in Figure 
6.2, the raw (Figure 6.3A top) and bandpass filtered (3-7 Hz; Figure 6.3A middle) LFP signals 
revealed increased power in the tremor frequency band during epochs of TJMs (Figure 6.3A left, 
red), but not during bouts of quiescence (Figure 6.3A right, blue). The LFP signal was indexed 
during epochs of TJMs and no TJMs as indicated by EMG event markers or lack thereof, 
respectively. Spectrograms of the raw signal revealed differential patterns of LFP activity for 
bouts of TJMs and quiescence (Figure 6.3A bottom). The power spectrum of the raw LFP signal 
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filtered for tremor frequencies (3-7 Hz) during epochs of TJMs (red) and no TJMs (blue) 
indicated strong LFP power in the tremor range with a peak at ~4 Hz for bouts of TJMs, while 
little LFP power existed at such frequencies for bouts lacking TJMs. At a simultaneously 
recorded STN site, the same pattern of activity was present (Figure 6.3B). Overall, the bandpass 
filtered LFP signal (3-7 Hz) during bouts of TJMs and the subsequent power spectrum of that 
signal revealed strong power in the 3-7 Hz range, whereas bouts of quiescence did not exhibit 
this effect (Figure 6.3B).  
Summary data from all animals revealed the same pattern of effects. Overall, M1 LFPs 
during TJM epochs (red) exhibited significantly more power in the 3-7 Hz range as compared to 
no TJM (blue) epochs (Figure 6.3C; t(18) = 5.13, p < .05).  The same pattern of activity existed 
for STN recording sites (Figure 6.3C, right; t(18) = 4.55, p < .05).  Further, M1 exhibited more 
power in the tremor band during TJM and no TJM epochs compared to STN (TJM: t(18) = 3.47, 
p < .05; no TJM: t(18) = 3.26, p < .05). Analysis of centroid frequency (Figure 6.3D) revealed no 
differences between bouts of TJMs and no TJMs within a given brain area (e.g., M1 TJM vs. M1 
no TJM; M1: t(18) = -0.79, p > .05; STN: t(18) = -0.36, p > .05 ).  Moreover, there were no 
significant differences in LFP centroid frequency between TJM and no TJM epochs across brain 
areas (e.g., M1 TJM vs. STN TJM; TJM: t(18) = 0.51, p > .05; No TJM: t(18) = 1.88, p > .05). 
 
Beta band power does not increase during TJMs in M1 and STN 
 Simultaneously recorded M1 LFPs for the animal shown in Figure 6.2 and 6.3, revealed 
similar LFP beta band power during epochs of TJMs (Figure 6.4A left, red) and epochs of 
quiescence (Figure 6.4A right, blue) for the raw (Figure 6.4A top) and bandpass filtered (15-30 
Hz; Figure 6.4A middle) LFP signals. Importantly, the data shown here are for the same time 
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points as presented in Figure 6.2 and 6.3, but here data were filtered for beta (15-30 Hz) instead 
of tremor frequencies (3-7 Hz). A closer look at the signal revealed similar instantaneous 
fluctuations in the LFP during active (Figure 6.4A bottom, left) and quiet (Figure 6.4A bottom, 
right) bouts. The power spectrum of the raw LFP signal filtered for beta band activity during 
epochs of TJMs (red) and no TJMs (blue) revealed strong LFP beta band power, but no 
alterations in power across behavioral state (e.g., bouts of TJMs vs. no TJMs). At a 
simultaneously recorded STN site, the same pattern of activity was present (Figure 6.4B).   
Overall, the bandpass filtered LFP signal (15-30 Hz) and subsequent power spectrum of that 
signal during epochs of TJMs and quiescence revealed no differences in beta band power (Figure 
6.4B).  
Summary data from all animals demonstrate the same trend as represented in Figure 
6.4A/B. Overall, M1 LFPs during TJM epochs (red) and no TJM epochs (blue) exhibited similar 
levels of beta band power (Figure 6.4C; t(18) = 1.48, p > .05).  For STN, the same pattern of 
activity existed (Figure 6.4C, right; t(18) = 0.65, p > .05). Further, M1 exhibited higher beta band 
power during epochs of TJMs and no TJMs as compared to STN (TJM: t(18) = 2.76, p < .05; no 
TJM: t(18) = 3.12, p < .05).  Moreover, TJM epochs exhibited lower centroid beta band 
frequency compared to no TJM epochs for both M1 and STN (Figure 6.4D; M1: t(18) = -2.84, p 
< .05; STN: t(18) = -3.57, p < .05, respectively).  Further, beta band frequency was higher in M1 
during TJM epochs compared to STN (t(18) = 3.63, p < .05).  Alternatively, there was no 
difference in beta band frequency between M1 and STN during periods of quiescence (t(18) = -
0.47, p > .05). 
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Figure 6.1: Verification of electrode placements. A (top): Photomicrographs of four 
representative and simultaneously recorded sites in M1. Middle and right photomicrographs 
show 4x and 10x close-up of electrode tips, respectively. A (bottom): Same as A (top) but for a 
different animal.  B (top): Photomicrographs of a representative recording site in STN. Middle 
and right photomicrographs show a 4x and 10x close-up of electrode tips, respectively. B 
(bottom): Same as B (top) but for a different animal.   
 
75 	  
 
Figure 6.2: Pilocarpine induces TJMs in the tremor frequency range as reflected by EMG 
activity. A (top): EMG electrode trace bandpass filtered for EMG frequency (500-1500 Hz) and 
full wave rectified during a long epoch of TJMs (red; 7.3 seconds) for a representative animal.  
The spectrogram indicates the same pattern of rhythmic activity as the EMG trace. A (bottom): 
Same animal and recording as presented in A, but for a long period of quiescence (blue; 7.3 
seconds). The spectrogram indicates little rhythmic activity during bouts lacking TJMs. B: Power 
spectrum of the EMG envelope for the same traces as presented in A. As can be seen, there is 
clear 3-7 Hz rhythmicity and strong harmonics during TJM epochs, which is absent during 
periods of quiescence. C (left): Power spectrum of the entire pilocarpine recording for the same 
animal as presented in A and B. C (right): Behavior of the same animal as presented previously 
across the entirety of the pilocarpine recording.   
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Figure 6.3A: Power in tremor frequency band increases during TJMs in M1. Top: Raw and 
bandpass filtered (3-7 Hz; middle) M1 LFP traces during epochs of TJMs (red) and no TJMs 
(blue) for the same representative animal presented in Figure 6.2. Bottom: Corresponding 
spectrograms for the raw M1 signal presented in the top panel during TJM and no TJM epochs. 
Overall, the spectrograms indicate rhythmicity in the LFP during periods of TJMs that is lacking 
during periods of quiescence. Right: Power spectrum of the bandpass filtered LFP signal 
presented in the middle panel during the TJM and no TJM epoch. Tremor frequency power 
increases substantially during periods of TJMs, while little tremor power exists during epochs of 
quiescence.  
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Figure 6.3B: Power in tremor frequency band increases during TJMs in STN. Top: Raw and 
bandpass filtered (3-7 Hz; middle) STN LFP traces during epochs of TJMs (red) and no TJMs 
(blue) for the same representative animal presented in Figure 6.2. Bottom: Corresponding 
spectrograms for the raw STN signal presented in the top panel during TJM and no TJM epochs. 
Overall, the spectrograms indicate rhythmicity in the LFP during periods of TJMs that is lacking 
during periods of quiescence. Right: Power spectrum of the bandpass filtered LFP signal 
presented in the middle panel during the TJM and no TJM epoch. Tremor frequency power 
increases substantially during periods of TJMs, while little tremor power exists during epochs of 
quiescence.  
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Figure 6.3 C and D: Summary data for tremor frequency power across all animals for TJM and 
no TJM epochs for M1 and STN. As can be seen, tremor band power dominates during the 
presence of TJMs, but not for bouts lacking TJMs. D: Summary data across all animals for 
tremor band centroid frequency as a function of TJM and no TJM epochs for M1 and STN 
recording sites. Overall, there were no differences in centroid frequency across behavioral state 
or brain area.   
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Figure 6.4A: Beta band power does not increase during TJMs in M1. Top: Raw and bandpass 
filtered (15-30 Hz; middle) M1 LFP traces during epochs of TJMs (red) and no TJMs (blue) for 
the same representative animal presented in Figure 6.2 and 6.3. Bottom: The first 1.4 seconds of 
the middle panel to show instantaneous LFP fluctuations. Right: Power spectrum of the bandpass 
filtered LFP signal presented in the middle panel during the TJM and no TJM epoch. Beta 
frequency power does not increase during periods of TJMs.  
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Figure 6.4B: Beta band power does not increase during TJMs in STN. Top: Raw and bandpass 
filtered (15-30 Hz; middle) STN LFP traces during epochs of TJMs (red) and no TJMs (blue) for 
the same representative animal presented in Figure 6.2 and 6.3. Bottom: The first 1.4 seconds of 
the middle panel to show instantaneous LFP fluctuations. Right: Power spectrum of the bandpass 
filtered LFP signal presented in the middle panel during the TJM and no TJM epoch. Beta 
frequency power does not increase during periods of TJMs.  
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Figure 6.4 C and D: Beta band power does not increase during TJMs in M1 and STN. C: 
Summary data for beta band power across all animals for TJM and no TJM epochs for M1 and 
STN. As can be seen, beta band power is similar during across behavioral states. D: Summary 
data across all animals for beta band centroid frequency as a function of TJM and no TJM 
epochs for M1 and STN recording sites.  
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Chapter 7: Discussion 
7.1 Summary of Results 
 The central aim of the present research was to characterize aspects of the instigation and 
treatment of Parkinsonian resting tremor using a pharmacological rodent model. These studies 
employed the TJM model, a rodent model of parkinsonian resting tremor, to investigate the 
neurochemical and electrophysiological changes that are associated with tremorogenesis. 
Furthermore, the TJM model was used to test the effects of both experimental and well 
established therapeutic agents. These studies collectively extended and validated the TJM model, 
contributing to the ultimate goal of this line of research, which is to characterize the conditions 
associated with tremorogenesis in order to develop specifically-targeted therapeutic strategies.    	  
In the first set of experiments, administration of the anticholinesterase galantamine was 
shown to induce tremulous jaw movements in mice. Coadministration of the adenosine A2A 
antagonist MSX-3 suppressed galantamine-induced TJMs. Freeze frame video analysis showed 
that the vast majority of galantamine-induced TJMs fell into the frequency range of 3-7.5 Hz, the 
frequency range characteristic of parkinsonian resting tremor. Coadministration of MSX-3 
produced a slight alteration of the relative frequency distribution of galantamine-induced TJMs 
by slowing the peak local frequency from approximately 6 Hz to 5 Hz.  
 The second set of experiments evaluated the ability of safinamide to attenuate resting 
tremor induced by three drug treatments with different mechanisms of action. Safinamide is a 
reversible and selective MAO-B inhibitor that also reduces DA uptake, blocks voltage-dependent 
sodium channels, modulates N-type calcium channels, and reduces glutamate release. 
Safinamide significantly suppressed TJMs induced by the anticholinesterase galantamine and the 
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muscarinic agonist pilocarpine. Safinamide also attenuated the TJMs, but not the locomotor 
suppression, induced by subchronic administration of the DA D2 antagonist pimozide.  
In the third group of experiments, the selective MAO-B inhibitor deprenyl suppressed 
TJMs induced by the VMAT-2 inhibitor tetrabenazine (TBZ). This study also employed in vivo 
microdialysis and HPLC to examine extracellular DA levels in the ventrolateral neostriatum 
(VLS). Administration of TBZ alone increased extracellular DA 30 minutes after injection, and 
reduced DA levels after 90 minutes compared to vehicle treated animals. Coadministration of 
deprenyl significantly increased extracellular DA in the later part of the session compared to rats 
treated with TBZ alone.  
The fourth set of experiments was performed to characterize the effects of the 
antidepressant fluoxetine (FLX) on motor dysfunctions induced by the VMAT-2 inhibitor TBZ. 
In the TJM paradigm, a low dose of TBZ produced a small but significant increase in TJMs 
compared to vehicle control, and coadministration of TBZ and FLX produced a dramatic 
increase in TJMs compared to TBZ alone. Furthermore, administration of FLX decreased 
locomotion compared to vehicle control, and co-administration of TBZ plus FLX significantly 
decreased locomotion compared to TBZ alone. TJMs induced by coadministration of TBZ and 
FLX were significantly suppressed by administration of the 5-HT2A/2C antagonist mianserin. 
Finally, DA tissue levels in the VLS were examined after administration of TBZ, FLX, and 
mianserin. TBZ administration decreased DA tissue levels in the VLS compared to the vehicle 
condition, and coadministration of TBZ and FLX further decreased DA tissue levels compared to 
TBZ alone. Mianserin attenuated this effect, as co-administration of mianserin in combination 
with TBZ and FLX increased DA tissue levels compared to the TBZ/FLX condition.  
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In the fifth set of experiments, LFPs from the primary motor cortex and subthalamic 
nucleus and EMG from the lateral temporalis muscle were simultaneously recorded in rats after 
administration of the muscarinic agonist pilocarpine. Pilocarpine administration induced TJMs 
that fell into the frequency range associated with Parkinsonian resting tremor (3-7 Hz). The 
induction of TJMs by pilocarpine was associated with strong rhythmicity in the envelope of the 
EMG signal with a peak frequency of approximately 4 Hz along with robust second and third 
harmonics. This EMG activity was accompanied by an increase in power at tremor frequency (3-
7 Hz) in M1 and the STN. Tremor activity was not associated with increased activity in the beta 
frequency band. 
 
7.2 Induction of oral tremor in mice by the acetylcholinesterase inhibitor galantamine: 
Reversal with adenosine A2A antagonism 
 The present studies investigated the ability of the anticholinesterase galantamine to 
induce TJMs in mice. The TJM model is a widely used model of Parkinsonian resting tremor that 
has been extensively validated in rats (Salamone et al., 1998, 2005, 2008b; Simola et al., 2004, 
2006; Kasture et al., 2009; Trevitt et al., 2009).  In order to provide cross-species validation of 
this model, researchers have made recent efforts to extend the TJM model to mice. Salamone et 
al. (2012) reported that administration of the muscarinic agonist pilocarpine induced TJMs in 
mice that fall into the frequency range of 3-7.5 Hz and can be attenuated by co-administration of 
the adenosine A2A antagonist MSX-3, or by conditional neural knockout of the adenosine A2A 
receptor. Furthermore, administration of the DA-depleting agent tetrabenazine induced TJMs in 
mice, which were attenuated by antagonism of the A2A receptor with MSX-3, or by conditional 
neural knockout of the A2A receptor (Podurgiel et al., 2013a). 
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 Anticholinesterases are currently the primary treatment for cognitive dysfunction 
associated with Alzheimer’s disease. Patients taking tacrine (Cognex), as well as the more 
recently developed anticholinergics such as donepezil, rivastigmine and galantamine, have been 
reported to experience improved cognition, but may develop Parkinsonian symptoms, including 
tremor, as a side effect (Ott and Lannon, 1992; Shea et al., 1998; Arai, 2000; Aarsland et al., 
2003; Emre et al., 2004;  Litvinenko et al., 2008; Song et al., 2008; Grace et al., 2009; van Laar 
et al., 2010). When administered to rats, galantamine induces TJMs that occur in the 3-7.5 Hz 
frequency range, and these movements were attenuated by co-administration of the adenosine 
A2A antagonists MSX-3 and MSX-4 (Collins et al., 2011; Santerre et al., 2012). Consistent with 
these known tremorogenic properties of galantamine in rats, the present results show that 
galantamine significantly induces TJMs in mice in a dose-dependent manner (see Figure 2.1).  
 Galantamine-induced TJMs were significantly reduced by co-administration of the 
adenosine A2A antagonist MSX-3 (see Figure 2.2).  This observation is consistent with previous 
research showing that adenosine A2A antagonists can produce antiparkinsonian effects in animal 
models (Wardas et al., 2001; Pinna et al., 2007; Morelli et al., 2010) as well as human studies 
(LeWitt et al., 2008; Mizuno and Kondo, 2013).  Moreover, these results support the observation 
that adenosine A2A receptor antagonism suppresses tremor in rodents (Correa et al., 2004; Simola 
et al., 2004, 2006; Tronci et al., 2007; Salamone et al., 2008a, 2013; Podurgiel et al., 2013a) and 
humans (Bara-Jimenez et al., 2003). The direct mechanism through which adenosine A2A 
receptor antagonism interacts with cholinergic transmission to suppress tremorogenesis is 
unclear, however, there is considerable evidence indicating that the neostriatum is a critical site 
for the generation of TJMs in rats (Salamone et al., 1990, 1998, 2008a,b; Finn et al., 1997), and 
adenosine A2A receptors are expressed in high concentrations in neostriatal enkephalin-positive 
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neurons (Ferré et al., 1997, 2001, 2008; Svenningsson et al., 1999; Chen et al., 2001; Fuxe et al., 
2004). Furthermore, several studies in rats have shown that adenosine A2A antagonism alters 
production of signal transduction markers such as cFos and pDARPP-32(Thr34) in putative or 
identified enkephalinergic striatal neurons (Betz et al., 2009; Santerre et al., 2012; Podurgiel et 
al., 2013a; Nunes et al., 2013). Thus, it is possible the adenosine A2A antagonists such as MSX-3 
are acting on enkephalin-positive striatopallidal neurons that form part of the so called “indirect 
pathway” in the basal ganglia circuitry, and that this action is capable of reducing the TJMs 
induced by DA antagonism and DA depletion (Betz et al., 2009; Podurgiel et al., 2013a), as well 
as cholinomimetic drugs. 
Experiment 3 examined the local frequency of TJMs after administration of galantamine 
alone, and after co-administration of galantamine and MSX-3. Figure 2.3 shows the relative 
frequency distribution (i.e., expressed as a percent of total) of the inter-movement intervals for 
each TJM observed in the video analysis.  The inter-movement interval is a useful measure 
because it is the reciprocal of the local frequency of movement (i.e., 200 ms inter-movement 
interval = 5 Hz).  As hypothesized, the vast majority of galantamine-induced TJMs fell into the 
frequency range of 3-7.5 Hz. Although the neural circuitry that generates the underlying 
rhythmicity of TJMs is unknown, it does appear that in both rats and mice, the peak frequencies 
for TJMs induced by DA antagonism, DA depletion, muscarinic agonists and anticholinesterases 
all fall within the 3.0-7.5 Hz range, which is similar to that seen in Parkinsonian resting tremor 
(Salamone et al., 1998; Collins-Praino et al., 2011; Ishiwari et al., 2005; Podurgiel et al., 2013a). 
In experiment 3, co-administration of MSX-3 reduced the total number of TJMs, as seen in 
experiment 2. In addition, MSX-3 produced a slight alteration of the relative frequency 
distribution of galantamine-induced TJMs (i.e., as indexed by the significant bin x drug treatment 
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interaction), apparently by slowing the peak local frequency from approximately 6 Hz (bin 5 = 
5/30 sec inter-movement interval) to 5 Hz (bin 6 = 6/30 sec inter-movement interval).    
Taken together, these results establish a mouse model of cholinomimetic-induced TJMs 
using the anticholinesterase galantamine, and thereby give researchers an additional avenue for 
investigating drug-induced Parkinsonism and tremorogenesis. Moreover, these results strengthen 
the literature demonstrating that adenosine A2A antagonists have anti-tremor effects.  Future 
studies should examine the effects of galantamine administration on tremor generation in mice 
with various genetic manipulations that are related to Parkinsonism.  
 
7.3 Tremorolytic effects of safinamide in animal models of drug-induced parkinsonian 
tremor  
The studies presented in chapter 3 were conducted to determine if safinamide is capable 
of reversing the oral tremor induced by galantamine, pilocarpine, and pimozide, using the well 
established tremulous jaw movement model. The results described above demonstrate that 
safinamide suppressed tremor in all three experiments, which to our knowledge is the first 
demonstration of the tremorolytic effects of safinamide. In the first experiment, all seven doses 
of safinamide tested (0.312 mg/kg to 10.0 mg/kg) were capable of reversing galantamine-
induced tremulous jaw movements. In the second experiment, three of the seven doses of 
safinamide tested (0.625 mg/kg, 5.0 mg/kg, 10.0 mg/kg) were able to attenuate tremulous jaw 
movements induced by pilocarpine. In the final experiment, both tremulous jaw movements and 
locomotion were assessed as in the Salamone et al. (2008a) paper. In that study, it was shown 
that subchronic administration of 1.0 mg/kg of the DA D2 antagonist pimozide induced 
tremulous jaw movements and reduced locomotion, relative to vehicle-treated rats. Three of the 
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seven doses tested (1.25 mg/kg, 5.0 mg/kg, 10.0 mg/kg) were capable of reducing pimozide-
induced tremulous jaw movements. Thus, across three different drug treatments, which have 
different mechanisms of action and generate different levels of tremor activity, safinamide was 
effective at reducing tremor. In the present study, although safinamide consistently attenuated 
tremulous jaw movements, it did not reverse the locomotion suppression induced by pimozide. It 
is not clear why safinamide failed to reverse the suppression of locomotion induced by pimozide, 
because other putative antiparkinsonian drugs, such as adenosine A2A antagonists, are capable of 
inducing locomotor activity in pimozide-treated animals at doses that also reduce tremor 
(Salamone et al. 2008a).  It is possible that safinamide is particularly effective at reducing tremor 
because of some specific neurochemical actions of the compound, but this remains to be 
determined. 
The ability of safinamide to reverse tremulous jaw movements induced by galantamine, 
pilocarpine, and pimozide is consistent with previous animal research demonstrating the 
antiparkinsonian properties of safinamide (Salvati et al. 1999; Fariello et al. 2000; Onofrj et al. 
2008 Schapira 2010). Additionally, our results are consistent with data from clinical studies. In 
the few published studies on the efficacy of safinamide in Parkinson’s disease patients, results 
show that safinamide is capable of treating motor impairments (Stocchi et al. 2004, 2006; Onofrj 
et al. 2008; Schapira 2010). When administered to early Parkinson’s disease patients, 37.5% 
revealed a 30% or greater improvement in the Unified Parkinson’s Disease Rating Scales 
(UPDRS III) score at the end of the study versus baseline (Stocchi et al. 2004). Additionally, 
when administered to Parkinson’s disease patients as an add-on therapy to a DA agonist, 47.1% 
showed improvement (Stocchi et al. 2004).  
The mechanism of action through which safinamide acts to suppress parkinsonian 
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symptoms in humans, or drug-induced tremors in rats, is uncertain.  As described above, 
safinamide is an inhibitor of MAO-B, and also blocks DA uptake, effects that lead to an 
elevation of extracellular DA (Marzo et al. 2004; Fariello 2007; Binda et al. 2007; Onofrj et al. 
2008 Schapira 2010; Stocchi 2012).  However, non-dopaminergic strategies also are becoming 
increasingly important in the development of drug treatments for parkinsonian symptoms. 
Neostriatal DA interacts with several other transmitters in the circuitry of the basal ganglia, 
including glutamate, GABA, serotonin, adenosine, and acetylcholine (DeLong, 1990; Hauber, 
1998; Obeso et al. 2000; Young and Penney, 1993).  Thus, it is possible that some of the non-
dopaminergic actions of safinamide, including effects on sodium channels, calcium channels, 
and glutamate release, also would lead to antiparkinsonian effects (Onofrj et al. 2008; Schapira 
2010; Stocchi 2012).  Safinamide has anticonvulsant properties (Fariello et al. 1998), and it has 
been suggested that there are fundamental similarities between the physiology that underlies the 
production of seizures and tremorogenesis (Buzsaki et al. 1990; Salamone et al. 1998).  Further 
research will be necessary to elucidate the specific mechanism through which safinamide exerts 
its effects on motor dysfunctions, including tremor, which are related to parkinsonism. 
 
7.4 MAO-B inhibition attenuates Parkinsonism induced by the VMAT-2 inhibitor 
tetrabenazine 
The studies in chapter 4 were performed to determine the effect of administration of the 
selective MAO-B inhibitor deprenyl on the TJMs induced by the VMAT-2 inhibitor 
tetrabenazine in rats. Our lab has previously established a pharmacological rodent model of 
Parkinsonism using TBZ, showing that TBZ administration induces tremulous jaw movements, 
catalepsy, and locomotor suppression in rats (Podurgiel et al., 2013a). These motor abnormalities 
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can be attenuated by coadministration of the adenosine A2A antagonist MSX-3, a putative 
antiparkinsonian agent (Podurgiel et al., 2013a). Until the present work, MSX-3 had been the 
only antiparkinsonian agent used to assess TBZ-induced TJMs. Given the importance of 
validating animal models, experiment 1 examined the ability of the well-established 
antiparkinsonian agent deprenyl to suppress tremor induced by TBZ. While MSX-3 exerts its 
antiparkinsonian properties via antagonism of adenosine A2A receptors, deprenyl acts to 
selectively inhibit MAO-B, one of the primary enzymes responsible for DA metabolism in the 
brain (Youdim and Bakhle, 2006). As predicted, results from experiment 1 showed that 
administration deprenyl significantly attenuated TBZ-induced TJMs. These results are consistent 
with clinical reports demonstrating the antiparkinsonian properties of deprenyl (Schapira et al., 
2011; Riederer P, Laux G, 2011; Fabbrini et al., 2012) and provide validation for the use of TBZ 
as a rodent model for assessment of drugs, as researchers have now shown that TBZ-induced 
Parkinsonism can be attenuated by two antiparkinsonian agents with different mechanisms of 
action, an adenosine A2A antagonist (Podurgiel et al., 2013a) and a MAO-B inhibitor. 
Furthermore, this experiment is the first to show that a selective MAO-B inhibitor is capable of 
attenuating TJMs in rodents. A previous study from our lab has shown that safinamide is capable 
of attenuating TJMs induced by a muscarinic agonist, anticholinesterase, and dopamine 
antagonist (Podurgiel et al., 2013b; Chapter 3). While safinamide does reversibly inhibit MAO-
B, it also reduces dopamine uptake, blocks voltage-dependent sodium channels, modulates N-
type calcium channels, and reduces glutamate release (Marzo et al., 2004; Onofrj et al., 2008).  
The second experiment examined extracellular DA levels in the ventrolateral striatum 
(VLS), after administration of TBZ alone, and coadministration of TBZ and deprenyl. The VLS 
is the neostriatal area most closely related to the production of TJMs, as it has been shown to be 
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responsible for orofacial movements and forepaw motor control (Salamone et al., 1990; Jicha 
and Salamone, 1991; Salamone et al., 1993). Previous work has demonstrated that TJMs induced 
by the DA D2 antagonist pimozide could be attenuated by local injections of MSX-3 into the 
VLS (Salamone et al., 2008a). Results from experiment 2 showed that administration of TBZ 
alone resulted in a substantial increase (100%) in extracellular DA 30 minutes after injection, 
followed by a significant reduction (50%) after 90 minutes compared to vehicle treated animals. 
This biphasic effect of TBZ on striatal DA is consistent with previous literature, and this early, 
short-lived increase in extracellular DA can likely be attributed to an initial build-up of 
intracellular DA due to a blockade of storage, and possibly a subsequent reversal of the DA 
transporter (Andersson 2006). It is reasonable to suggest that as time goes by, intracellular MAO 
has degraded a substantial percentage of the unstored cytosolic DA molecules, resulting in the 
observed decrease in extracellular DA, which is maintained for 60 minutes. Consistent with the 
behavioral data in experiment 1, coadministration of deprenyl blunted the neurochemical actions 
of TBZ, as deprenyl significantly increased extracellular DA compared to rats treated with TBZ 
alone in the latter part of the microdialysis session. It is likely that this occurred because 
inhibition of MAO-B by deprenyl would have prevented the enzymatic breakdown of the 
cytosolic, non-vesicular fraction of the DA pool.  
Taken together, these results provide evidence validating the use of TBZ as a rodent 
model of drug-induced Parkinsonism. Future studies should continue to validate and utilize this 
model to examine putative antiparkinsonian agents, and provide further insight into the 
mechanisms associated with tremorogenesis.  
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7.5 Fluoxetine administration exacerbates oral tremor and striatal dopamine depletion in a 
rodent pharmacological model of Parkinsonism  
The present studies were undertaken to characterize the effects of the antidepressant FLX 
on motor dysfunctions, particularly the oral tremor marked by TJMs, which are induced by the 
VMAT-2 inhibitor TBZ. These drugs were selected because Huntington’s disease patients 
prescribed TBZ for the treatment of chorea may experience Parkinsonism and depression as 
adverse events (Kenney et al., 2007; Frank, 2009; Guay, 2010), and also because SSRIs such as 
FLX are frequently used to treat depression associated with Parkinsonism (Veazey et al., 2005; 
Aarsland et al., 2009; Chen and Marsh, 2013; Schreiber and Thompson, 2013). Administration of 
high doses of TBZ (e.g. 2.0 mg/kg) in rats has been used as a pharmacological rodent model of 
Parkinsonism (Podurgiel et al., 2013a), while lower doses such as 0.75 mg/kg are used to model 
motivational symptoms of depression (Nunes et al., 2013; Randall et al., 2014). Experiment 1 
showed that a low dose of TBZ (0.75 mg/kg) produced a small but significant increase in TJMs 
compared to the vehicle condition, and this effect of TBZ was dramatically enhanced by co-
administration of  FLX (2.5, 5.0, or 10.0 mg/kg), which significantly increased TJMs compared 
to TBZ alone. Additionally, administration of FLX (10.0 mg/kg) significantly decreased 
locomotion compared to vehicle control, and co-administration of TBZ (0.75 mg/kg) plus FLX 
(2.5, 5.0, 10.0 mg/kg) significantly decreased locomotion compared to TBZ alone. Thus, results 
from experiment 1 showed that FLX administration exacerbates Parkinsonian-like motor 
dysfunctions induced by a low dose of TBZ in rats. These results are consistent with studies 
showing potentiation of haloperidol-induced motor impairments (e.g. catalepsy and 
bradykinesia) by FLX in rodents (Tatara et al., 2012), and with numerous clinical reports linking 
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motor side effects and worsening Parkinsonism with FLX treatment of depression (Leo, 1996; 
Gerber and Lynd, 1998; Govoni et al., 2001; Madhusoodanan et al., 2010).  
 Previous research has demonstrated that 5-HT is involved in the modulation of drug and 
lesion-induced TJMs.  Stewart et al. (1987) reported that pilocarpine-induced vacuous chewing-
like movements were reduced by co-administration of para-chlorophenylalanine, which blocks 5-
HT synthesis and depletes central 5-HT stores. Evidence also indicates that 5-HT2 family 
receptors are involved in the regulation of TJM activity. Atypical antipsychotic drugs that act as 
5-HT2 family antagonists or inverse agonists generally fail to induce TJMs, and in fact can 
suppress the TJMs induced by cholinomimetic drugs (Salamone et al., 1998; Betz et al., 2005, 
2009). Furthermore, the 5-HT2A/2C receptor antagonist mianserin was shown to suppress the 
TJMs induced by the 5-HT agonists m-chlorophenylpiperazine and quipazine (Stewart et al., 
1989), as well as anticholinesteraste tacrine (Carlson et al., 2003).  In view of these previous 
findings, experiment 2 investigated the ability of mianserin to attenuate the TJMs induced by co-
administration of TBZ (0.75 mg/kg) and FLX (5.0 mg/kg). The results showed that 
administration of mianserin (2.5, 5.0 mg/kg) significantly reduced the number of TJMs induced 
by co-administration of TBZ and FLX, thereby indicating that FLX exacerbates TJMs via 
activation of 5-HT2A and/or 5-HT2C receptors. Although mianserin is nonselective for different 
subtypes of 5-HT2 receptors, previous work has shown that the rank order of potency for the 
suppression of tacrine-induced TJMs by atypical antipsychotics is related to their affinity for 5-
HT2A receptors (Betz et al., 2005), and also that the selective 5-HT2A inverse agonist ACP-103 
could reduce tacrine-induced TJMs (Vanover et al., 2008).  Future studies should investigate the 
effects of selective antagonists or inverse agonists of 5-HT2A and 5-HT2C receptors on the 
fluoxetine-induced enhancement of tetrabenazine-induced TJMs. 
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Previous research has shown that the VLS is the neostriatal region most closely 
associated with the production of TJMs (Kelley et al., 1989; Salamone et al., 1990, 1998, 2008; 
Jicha and Salamone, 1991; Betz et al., 2009), and that DA depletion in the VLS, but not other 
striatal subregions, induces TJMs in rats (Jicha and Salamone, 1991).  Therefore, in order to 
determine if changes in striatal DA levels are related to the pattern of behavioral effects observed 
in experiments 1 and 2, experiment 3 examined DA tissue levels in the VLS of rats after 
administration of TBZ (0.75 mg/kg), FLX (5.0 mg/kg) and mianserin (5.0 mg/kg). As predicted, 
TBZ administration decreased DA tissue levels in the VLS compared to the vehicle condition. 
Consistent with the pattern of effects observed in the behavioral experiments, co-administration 
of TBZ and FLX further decreased DA tissue levels compared to TBZ alone, and mianserin 
attenuated this effect, with co-administration of mianserin in combination with TBZ and FLX 
increasing DA tissue levels compared to the TBZ/FLX condition.  
The precise mechanisms through which FLX enhances the TJMs induced by TBZ is not 
clear.  Although one cannot completely discount the possibility of specific pharmacodynamic or 
pharmacokinetic interactions between these two particular drugs, it is important to emphasize 
that motor dysfunctions induced by FLX or other 5-HT uptake inhibitors have been reported to 
occur in humans and other animals under conditions in which a variety of other drugs were being 
administered, and even when no other drugs were being given. Furthermore, the ability of 
mianserin to reduce TJMs has been observed under a variety of conditions, including cases in 
which either a 5-HT agonist (Stewart et al., 1989) or an anticholinesterase (Carlson et al., 2003) 
was being administered.  The present results are consistent with a substantial literature 
demonstrating serotonergic modulation of TJMs across a broad array of pharmacological 
conditions (Stewart et al., 1987, 1989; Salamone et al., 1998; Carlson et al., 2003; Betz et al., 
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2007; Vanover et al., 2008). Serotoninergic neurons from the raphe nucleus project to the 
dopaminergic midbrain nuclei (substantia nigra pars compacta and ventral tegmental area), as 
well as to their target structures, the striatum and nucleus accumbens (Michelsen et al., 2007). 
The 5-HT2 receptor family, with particular emphasis on the 5-HT2A and 5-HT2C receptor 
subtypes, has been implicated in serotonergic modulation of mesolimbic and nigrostriatal DA 
activity (Di Giovanni et al., 1999; Di Matteo et al., 2000; Porras et al., 2002; Alex et al., 2005; 
Alex and Pehek, 2007), though it is unclear how these physiological interactions are related to 
the present findings. Prototypical SSRIs like FLX block uptake of 5-HT from the synapse by 
inhibiting the 5-HT transporter, resulting in increased synaptic levels of 5-HT and increased 
activation of 5-HT receptors (Nutt et al., 1999). Furthermore, FLX treatment has been shown to 
reduce levels of DA and its metabolite in the neostriatum of mice (Morelli et al., 2011). Based 
upon the present results, it is reasonable to hypothesize that FLX administration may be 
enhancing the TJMs induced by TBZ by reducing DA tissue levels in VLS, an effect that is 
mediated via increased stimulation of 5-HT2A and/or 5-HT2C receptors. Nevertheless, interactions 
involving other brain areas (e.g. substantia nigra) and neurotransmitters (e.g. acetylcholine) may 
also be important.  
Overall, the results from this study indicate that acute FLX administration exacerbates 
drug-induced Parkinsonism in a pharmacological rodent model, possibly due to increased 
stimulation of 5-HT2A and/or 5-HT2C receptors.  Since antidepressant drugs are typically given 
chronically, future studies should also examine the effects of long-term administration of FLX 
and other SSRIs. These results have significant implications for understanding the movement-
related adverse events, including tremor, which are induced by FLX (Brambilla et al., 2005; 
Madhusoodanan et al., 2010), and the complications that may result from the continued use of 
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FLX in patients with idiopathic or drug-induced Parkinsonism, particularly in view of evidence 
suggesting that SSRIs may be no more effective than placebo in treating PD-related to 
depression (Skapinakis et al., 2010; Aarsland et al., 2009).   
 
7.6 Tremor-related subthalamic and cortical local field potentials associated with 
pilocarpine-induced oral tremor 
 Previous research has shown that the muscarinic agonist pilocarpine is a tremorogenic 
agent. Pilocarpine induces a robust TJM response in the 3-7 Hz frequency range that is reduced 
by antiparkinsonian agents (Salamone et al., 2005; Betz et al., 2007; Collins et al., 2010; 
Podurgiel et al., 2013b), conditional neural knockout of adenosine A2A receptors (Salamone et 
al., 2013), and deep brain stimulation of the STN (Collins-Praino et al., 2013). Evidence 
indicates that the TJMs induced by pilocarpine are due to stimulation of M2 or M4 muscarinic 
receptors in the ventrolateral neostriatum of the rat, which is the homologue of the ventral 
putamen of primates (Salamone et al., 1990, 1998; Mayorga et al., 1997, 1999). For these 
reasons, pilocarpine was selected for the present studies in order to induce a robust oral tremor 
that would allow for the assessment of tremor-related cortical and subthalamic LFP activity. 
 Network activation as measured by LFP activity in M1 and STN can be used as a tool to 
better understand transient dynamics across distributed neural networks. Similar to analysis of 
variations in the blood-oxygen-dependent signal used in functional neuroimaging (Logothetis 
and Wandell, 2004; Law et al., 2005), detailed analysis of mesoscopic signals such as the LFP 
and EEG reveal the engagement of distributed neural circuits in relation to tremorogenesis—a 
cardinal symptom of Parkinsonism.  Abnormalities in long-range connectivity between brain 
areas have been postulated as an important pathophysiological mechanism underlying brain 
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dysfunctions (Hutchison et al., 2004; Mallet et al., 2008).  However, it remains unclear how 
perturbed connectivity relates to motor symptoms such as tremorogenesis, and how it is 
manifested in the dynamic interactions of neuronal circuits. 
In the present study, we simultaneously recorded LFPs from the primary motor cortex 
and subthalamic nucleus as well as EMG from the lateral temporalis muscle in a rat model of 
drug-induced tremor. The temporalis was chosen because of previous research indicating that 
activity of this jaw closing muscle is a critical marker of observable TJM activity (Cousins et al., 
1998). The present results indicate that administration of the muscarinic agonist pilocarpine 
induces TJMs in rats that fall into the frequency range associated with Parkinsonian resting 
tremor (3-7 Hz), with a peak frequency of approximately 4 Hz, and harmonics at higher 
frequencies. These data are consistent with previous studies indicating that cholinomimetic 
drugs, including muscarinic agonists and anticholinesterases, can induce or exacerbate resting 
tremor. Administration of the anticholinesterase physostigmine to PD patients was reported to 
exacerbate parkinsonian symptoms, including tremor, and these motor deficits were attenuated 
by coadministration of centrally-acting muscarinic antagonists (Duvoisin 1967). For many 
decades, non-selective muscarinic receptor antagonists have been used to treat idiopathic and 
drug-induced Parkinsonism (McEvoy, 1983). Anticholinesterases are prescribed to treat the 
cognitive deficits associated with Alzheimer’s Disease (see Birks, 2006 for review), and these 
drugs have been shown to induce Parkinsonian symptoms, including tremor, as side effects (Ott 
and Lannon, 1992; Arai, 2000; Aarsland et al., 2003; Grace et al., 2009). In animal studies, 
muscarinic agonists such as tremorine and oxotremorine have been widely recognized to act as 
tremorogenic agents (Brimblecombe, 1975). Furthermore, muscarinic agonists and 
anticholinesterases induce TJMs in rodents, and co-administration of antiparkinsonian agents 
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including DA agonists, muscarinic antagonists, and adenosine A2A antagonists have been shown 
to reduce cholinomimetic-induced TJMs (Salamone et al. 1986; Baskin et al., 1994; Mayorga et 
al., 1997; Salamone et al., 1998; Simola et al., 2004, 2006; Miwa et al., 2009; Collins et al., 
2010a, 2011).  
 The induction of TJMs by pilocarpine was associated with strong rhythmicity in the 
envelope of the EMG signal with a peak frequency of approximately 4 Hz along with robust 
second and third harmonics, which is consistent with EMG recordings from the forearms of PD 
patients during periods of tremor (Liu et al., 2002; Timmerman et al., 2003; Wang et al., 2005; 
Reck et al., 2009; Hirschmann et al., 2013). This EMG activity was accompanied by an increase 
in power at tremor frequency (3-7 Hz) in M1 and the STN. In PD patients, pathological 
oscillatory neuronal activity in the open and closed loop connections between the cortex, basal 
ganglia, and thalamus is thought to underlie tremorogenesis (Hutchison et al., 2004). 
Simultaneously recorded magnetoencephalography and forearm EMG in PD patients has allowed 
researchers to characterize the cortical regions that are coherent with muscle activity during 
periods of resting tremor (Oswal et al., 2013). These studies indicate a strong coherence between 
EMG of forearm muscles and M1 activity at tremor frequency and its second harmonic 
(Timmerman et al., 2003).  
 Oscillatory activity in the STN of PD patients has been well characterized, as researchers 
are able to record LFPs from patients undergoing implantation of stimulating electrodes for deep 
brain stimulation. In recent years, the primary focus has been on increased oscillatory activity in 
the beta band (~15-30 Hz), since there is evidence that increased beta power in the STN is 
associated with motor control, particularly akinesia-rigidity (Brown et al., 2001; Levy et al., 
2002; Priori et al., 2004; Brown and Williams, 2005; Kuhn et al., 2006). Conversely, resting 
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tremor has not been shown to correlate with beta band activity in the STN of PD patients (Kuhn 
et al., 2005). Instead, the development of tremor has been associated with the emergence of 
oscillations in the tremor frequency range (3-7 Hz) as indicated by power spectra of STN LFPs, 
and coherence between STN LFPs and EMG activity at tremor frequency (Brown et al., 2001; 
Levy et al., 2000; Liu et al., 2002; Wang et al., 2005; Reck et al., 2009; Hirschmann et al., 2013). 
In a recent study by Hirschmann et al. (2013) the emergence of tremor in PD patients was shown 
to be associated with an increase of cerebral synchronization at tremor frequency and second 
harmonic in a network that includes both STN and M1. Additionally, in African green monkeys 
treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), the development of resting 
tremor was associated with the emergence of oscillations at tremor frequency in the STN 
(Bergman et al., 1994). Results from our experiment are line with the findings reported in the 
clinical and non-human primate studies, as we saw increased power in M1 and STN in the 
tremor, but not beta frequency range during periods of TJMs. Moreover, the present results are 
consistent with previous studies demonstrating that the STN is a critical part of the basal ganglia 
circuitry that is involved in motor dysfunctions related to Parkinsonism. Lesions or inactivation 
of STN have been shown to reverse motor dysfunctions in rodent models (Centonze et al., 2005; 
Baunez and Gubellini 2010). In addition, high frequency stimulation of STN has been reported to 
restore motor function in rodent models of Parkinsonism (Baunez 2011; Brown et al., 2011), and 
to attenuate drug-induced TJMs in rats (Collins-Praino et al., 2011).   
To date, this phenomenon has been well documented in the clinical literature, but very 
little has been done to study these oscillatory alterations in rodent models. It has, however, been 
shown that LFPs recorded from the frontal cortex and STN of rats with 6-hydroxydopamine 
lesions of midbrain dopaminergic neurons show increased power and coherence in the beta 
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frequency band (Sharott et al., 2005; Mallet et al., 2008). It should be noted that these studies 
were using a model that involved neurotoxic depletion of DA, whereas our study employed a 
model of drug-induced Parkinsonian resting tremor. In the present study, though the rats 
appeared to have reduced locomotion after pilocarpine administration, they were not completely 
akinetic, and occasionally moved about the chamber during recording. Therefore, our study 
specifically evaluated the physiological correlates of tremor by using an agent that induces a 
robust tremorogenic (i.e., TJM) response. By providing physiological and behavioral correlates 
of tremor, this model could be utilized in preclinical studies focused on the development of 
treatments that specifically target tremor. 
 
7.7 Conclusions and Future Directions  
The findings in the present research provide insight into aspects of the generation, 
maintenance, and treatment of Parkinsonian resting tremor. Experiment 1 established a mouse 
model of cholinomimetic-induced TJMs using the anticholinesterase galantamine, which gives 
researchers an additional platform for investigating drug-induced Parkinsonism and 
tremorogenesis. Results from this experiment also lend support the literature demonstrating the 
anti-tremor effects of adenosine A2A antagonists. Future studies should utilize this model to 
examine the effects of galantamine administration on tremor generation in mice with various 
genetic manipulations that are related to Parkinsonism.   
Results from experiment 2 support the use of safinamide as an adjunct to levodopa or DA 
agonists in PD patients, as it was effective in suppressing tremor induced by three different drug 
treatments with varying mechanisms of action. However, the precise mechanism of action 
through which safinamide acts to suppress Parkinsonian symptoms is uncertain. While it is a 
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potent, highly selective and reversible inhibitor of MAO-B, safinamide also reduces DA uptake, 
blocks voltage-dependent sodium channels, modulates N-type calcium channels, and reduces 
glutamate release. Further research is necessary to elucidate the specific mechanism through 
which safinamide exerts its effects on motor dysfunctions related to Parkinsonism.  
In experiment 3, coadministration of the MAO-B inhibitor deprenyl blunted the number 
of TJMs and the neurochemical actions induced by administration of the VMAT-2 inhibitor 
tetrabenazine. These results are consistent with the use of deprenyl for the treatment of the motor 
symptoms of PD, and provide additional validation for the use of TBZ as a rodent model of 
Parkinsonism. Future studies should continue to validate and utilize this model to examine the 
mechanisms associated with tremor generation, and evaluate potential antiparkinsonian agents.  
Furthermore, because relatively high doses of deprenyl were used in experiment 3, it is possible 
that effects on MAO-A could have contributed to the behavioral and neurochemical effects that 
were seen. Thus, future studies should try to determine if the results reported above were due to 
selective actions of deprenyl on MAO-B, or a combined effect of blockade of both isozymes. 
Results from experiment 4 indicate that acute FLX administration exacerbates drug-
induced Parkinsonism in a pharmacological rodent model, possibly due to increased stimulation 
of 5-HT2A and/or 5-HT2C receptors. These results have significant implications for the continued 
use of FLX in patients with idiopathic or drug-induced Parkinsonism, particularly in view of 
clinical evidence suggesting that SSRIs may be no more effective than placebo in treating PD-
related to depression. Results from this study contribute to the overall understanding of the 
movement-related adverse events that are induced by FLX, but since antidepressant drugs are 
typically given chronically, future studies should examine the effects of long-term administration 
of FLX and other SSRIs. 
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Results from experiment 5 parallel the findings reported in the clinical literature. In PD 
patients, the development of tremor has been shown to be associated with the emergence of 
oscillations in the tremor frequency range (3-7 Hz) in the cortex and subthalamic nucleus. While 
this phenomenon has been well characterized in PD patients, very little has been done to study 
these oscillatory alterations in rodent models. By providing physiological and behavioral 
correlates of tremor, this study establishes a model that could be utilized in preclinical studies 
focused on the development of treatments that specifically target tremor.  
Collectively, these studies provide extensive validation for the TJM model. Future 
research should continue to utilize the TJM model to further investigate the pathophysiological 
mechanisms associated with tremor generation, as well as to evaluate novel therapeutics for the 
treatment of this motor symptom. The results presented here help to characterize the conditions 
associated with tremorogenesis, and can hopefully contribute to the development of specifically-
targeted therapeutic strategies for the millions of patients suffering from Parkinsonism.  
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